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A.1 Background information 
 
Human Immunodeficiency Virus (HIV) infected patients frequently present with fever 
and peripheral cytopenias, which are often caused by disseminated infections and 
malignant disease (Miralles et al, 1995; Coyle et al, 1997; Benit et al, 1997; Armstrong 
et al, 1999). A bone marrow examination may identify underlying disease in some of 
these patients, with the reported diagnostic yield ranging from 27% to 42% (Bishburg et 
al, 1997; Brook et al, 1997; Luther et al, 2000; Pacios et al, 2004).  
 
There is a high demand for bone marrow biopsies on HIV-patients at Groote Schuur 
Hospital. A bone marrow biopsy is an invasive and expensive procedure.  In the 
background of limited resources and increasing number of HIV patients, questions are 
raised regarding the cost-effectiveness of this procedure and the possibility of selecting 
patients in whom this investigation would be more useful. 
 
The South African context 
 
South African studies investigating the utility of bone marrow biopsies in HIV-patients 
are sparse. Those performed, were done before the Highly Active Antiretroviral Therapy 
(HAART) era. The provision of HAART drugs was started in March 2004 in the public 
sector and is currently the largest Acquired Immune Deficiency Syndrome (AIDS) 
treatment program in the world. By September 2007, 370 000 individuals in the public 
sector and 120 000 attending private doctors had been enrolled nationally 
(UNAIDS/WHO, 2008). Due to severe cellular immunosuppression patients are at risk 
of concurrent opportunistic infections. Thus, ongoing management of opportunistic and 
HIV-related illnesses is required in HIV patients; either prior to starting Antiretroviral 
therapy (ART), during treatment or after treatment failure. A number of infectious and 
malignant disorders that may be reversed with effective therapies affect the bone 
marrow and can be elicited through a suitable biopsy. Research is required to develop 











individuals in South Africa and to predict the changing requirements for their care as the 
rollout of HAART becomes more established.  
 
For instance, the Western Cape has the highest worldwide annual tuberculosis (TB) 
notification rate (1000/100 000 individuals) (Meya et al, 2007). Early detection of this 
disease in our community is a priority and it is important to determine the role of bone 
marrow biopsies in this regard. 
 
Detection of infectious disease by bone marrow examination 
 
Investigations for infectious diseases include: microbiological cultures of the blood and 
bone marrow, bone marrow cytological assessment, histological evaluation for the 
presence of granulomata and the demonstration of micro-organisms by special staining 
techniques. Because the histological bone marrow examination occurs within days of 
collection and mycobacterial cultures take 3 to 6 weeks, a considerably quicker 
diagnosis of disseminated mycobacterial infections may be made on morphological 
examination prior to microbiology culture results. This allows the rapid institution of 
antimicrobial therapy which reduces morbidity and mortality (Nichols et al, 1991; 
Ciaudo et al, 1994; Benit et al, 1997; Hussong et al, 1998; Karstaedt et al, 2001).  
 
On the other hand, several studies showed bone marrow cultures to be more sensitive 
than bone marrow microscopy for the diagnosis of disseminated mycobacterial and 
fungal infections (Ker et al, 2002). One example is a study performed by Benit et al 
(1997), who assessed the role of a bone marrow biopsy in 123 HIV-patients who 
presented with pyrexia of unknown origin (PUO). TB was found in 18 patients and was 
confirmed by bone marrow culture in 10. Tuberculoid granulomata with acid-fast bacilli 
(AFB’s) were observed in 7 patients. The absence of AFB’s or granulomata in the bone 
marrow trephine biopsy does not exclude the eventual growth of organisms in bone 
marrow cultures (Prego et al, 1990). Cultures are useful for confirmation, identification 














Mycobacterial blood cultures are not taken routinely from patients suspected to have TB 
in South African hospitals. More emphasis is placed on sputum collection. However, 
blood cultures have been found to be equivalent to bone marrow cultures for the 
diagnosis of disseminated mycobacterial and fungal infections in AIDS-patients 
(Northfelt et al, 1991; Ciaudo et al, 1994; Ker et al, 2002; Pacios et al, 2004). Several 
authors recommend the use of a blood culture as the first step in the routine evaluation 
of AIDS patients when disseminated mycobacterial or fungal infections are suspected 
(Engels et al, 1995; Keiser et al, 1997; Kilby et al, 1998; Marques et al, 2000). However 
this practice is generally underutilized in the clinical work-up of these patients. This is 
likely due to financial constraints as the cost of a mycobacterial blood culture is 
approximately three hundred and twenty five rand, including sensitivity testing. 
 
Detection of malignant disease by bone marrow examination 
 
Non-Hodgkin lymphoma (NHL) occurs with a 60 – 200 fold increased frequency in 
HIV-positive compared with HIV-negative patients. Before HAART was available, 
Primary Central Nervous System (CNS) lymphoma and Burkitt lymphoma were 
increased approximately 1000 times in comparison with the general population. In 1985 
the United States Centre for Disease Control and Prevention included NHL as an AIDS-
defining condition. Since the introduction of HAART, the risk of NHL declined 
substantially and is consistent with improved CD4 counts. Burkitt lymphoma however, 
showed no evidence of a decline. Because HAART is associated with enhanced survival 
and a 75% decrease in mortality rate, lymphomas now contribute to a greater percentage 
of first AIDS-defining illness. (Beral et al, 1991; Levine et al, 1993; Cote et al, 1997; 
Appleby et al, 2000; Swerdlow et al, 2008). 
 
Bone marrow biopsies are frequently performed to exclude lymphoma in HIV-patients. 
These lymphoma patients may also present with fever and cytopenias. High-grade NHL, 











marrow involvement according to international literature. Thus the diagnostic sensitivity 
of a bone marrow examination demonstrated in the trephine biopsy by special staining 
techniques as the primary diagnostic procedure for the diagnosis of lymphoma is thought 
to be poor (Malyangu et al, 2000; Levine et al, 2002; Santos et al, 2004; Swerdlow et al, 
2008).  
 
In contrast with the low incidence of bone marrow involvement of Hodgkin Lymphoma 
(HL) in immune-competent patients, the incidence of bone marrow involvement in 
patients with HIV is higher, and the bone marrow may also be the site of primary 
diagnosis (Fend and Kremer, 2007). Before the era of HAART the incidence of HL in 
HIV-patients was increased by 8 fold (Hussong et al, 1998). There has been an 
unexpected increase in the incidence of this disease since the advent of HAART therapy 
and this is possibly related to improvements in CD4 counts (Beral et al, 1991; Swerdlow 
et al, 2008).  
 
Predictors of a positive bone marrow examination 
 
Several authors have previously compared the clinical and laboratory features of HIV-
patients with diagnostic versus non-diagnostic bone marrow biopsies in an attempt to 
identify predictive features. Some concluded that a bone marrow biopsy is most helpful 
in patients when fever and cytopenias co-exist rather than fever or cytopenias alone 
(Ciaudo et al, 1994; Brook et al, 1997; Llewelyn et al, 2005; Tanaka et al, 2006).  Keiser 
et al  (1997) reported that a CD4 count < 50 x 106/L and a haematocrit < 25% were 
predictive of a diagnostic bone marrow biopsy, while others found the bone marrow 
most likely to yield a diagnosis if the haematocrit is < 30% (Luther et al, 2000). In one 
of the few South African studies, Karstaedt et al (2001) identified wasting, oral thrush, 



















This study was performed to evaluate the diagnostic yield of bone marrow biopsies 




The study was structured with the following objectives: 
 
• To determine the diagnostic yield of a bone marrow biopsy to detect neoplastic, 
infectious and new haematological diseases (excluding non-specific changes 
found in HIV) by histopathological examination and microbiological 
investigations. 
• To determine the most frequent new diagnoses made. 
• To correlate the diagnostic yield of histopathology, bone marrow culture and 
peripheral blood culture results in the diagnosis of disseminated mycobacterial 
infections. 
• To compare the turnaround times (difference between the date sampled and the 
date reported positive) between positive mycobacterial bone marrow versus 
positive blood cultures. 
• To determine the correlation between the presence of granulomata in the bone 
marrow and the detection of AFB’s by Ziehl-Neelsen (ZN) staining. 

















A.3 Institutional approval 
 
This proposal was submitted for ethics approval to the University of Cape Town 




A retrospective review was performed on consecutive patients infected with HIV who 
had bone marrow biopsies performed at Groote Schuur Hospital between January 2004 
and December 2007. Statistical analysis indicated that a sample size of approximately 
150 patients would meet our requirements: assuming that the sample of 150 cases was 
representative of the study population and based on an estimated yield of 33%, there was 
an acceptable width (approximately 15%) to the 95% confidence interval. 
 
Groote Schuur Hospital serves as a tertiary referral centre in the Cape Town Central 
Health District of the Western Cape Metro region. HIV prevalence in this region is 
approximately 15,1% of the total population.  As a 936 bed, public sector university 
hospital, there are approximately 44 000 inpatient admissions and 575 000 outpatient 
attendances per year (www.capegateway.gov.za). The hospital offers specialized 
Infectious Disease and Anti-retroviral Clinics. Approximately 1000 bone marrow 




















• Patients who were HIV positive, as indicated by the clinician on the bone 
marrow request form. 
• Bone marrow biopsies for which the indications were fever, fever and cytopenias 
or cytopenias only. 
o Fever was defined as a documented temperature of ≥ 38 0C measured in 
the armpit. 
o Anaemia, leucopenia and thrombocytopenia were defined as levels below 
the National Health Laboratory Service (NHLS) reference ranges at sea 




• Patients below 18 years of age. 
• Staging bone marrow biopsies on patients with previously diagnosed lymphomas 
or other malignancies. 
• All follow-up bone marrow biopsies for previously diagnosed haematological 
diseases. 
• All bone marrow biopsies referred to Groote Schuur Hospital from other centers. 
 
The laboratory records of the selected cases were retrospectively reviewed. Files were 
sourced according to the laboratory specimen numbers. Clinical data was obtained from 
the patient’s Groote Schuur Hospital folders which were drawn from archives using the 
patient hospital numbers. The medical and laboratory information of the selected 
patients were entered onto a standardized data collection sheet (Annexure C). Only the 
laboratory number (under which the bone marrow biopsy was performed) was used as 
identification on the worksheet. The patient’s name and personal details were not 
recorded. Each case was then assigned a random number which was used during 
statistical analysis. The following information was collected:   
 
• Indication for the bone marrow biopsy. 











• Use of anti-retroviral therapy. 
• Prior diagnosis of tuberculosis. 
• Current tuberculosis treatment. 
• Prior diagnosis of lymphoma or another malignancy. 
• Laboratory results:  
o Absolute CD4 lymphocyte count result closest to the date of the bone 
marrow biopsy (performed by CD45-Assisted PanLeucogating 
methodology on the Epics XL-MCL Flow acidometer in the C17 NHLS 
Haematology Laboratory, Groote Schuur Hospital). 
o Peripheral blood counts and differential counts (performed on the Bayer 
Advia 2120 analyzer in the C17 NHLS Haematology Laboratory, Groote 
Schuur Hospital). 
o Results of bone marrow aspirate and peripheral blood mycobacterial 
cultures (performed on the BACTEC 9000 blood culture system in the 
NHLS Microbiology Laboratory, Groote Schuur Hospital). 
o Bone marrow histopathology results (reported in the NHLS Haematology 
Laboratory, Groote Schuur Hospital). 
• Results of ZN and modified ZN stains (retrospectively performed on all the bone 
marrow trephine biopsies). 
• Diagnosis made by bone marrow biopsy. A bone marrow biopsy was considered 
diagnostic when: 
o There was evidence of a haematologic disease, such as Immune 
Thrombocytopenic Purpura (ITP), Aplastic Anaemia, Pure Red Cell 
Aplasia or Megaloblastic Anaemia. 
o There was evidence of previously undiagnosed lymphoma or another 
malignancy. 
o There was evidence of a disseminated mycobacterial or fungal infection, 
either by morphologic examination (bone marrow granulomata or 
identification of micro-organisms by cytochemical staining) or a positive 











• Changes made to the patient’s management based on the bone marrow biopsy 
result. 
 
Bone marrow histology 
 
Bone marrow trephine biopsies were fixed in Zenker’s solution (which contains 
mercuric chloride, potassium dichromate and sodium sulphate) and decalcified in a weak 
acid as per standard operating procedures (Annexure D). Three-micrometer sections 
were cut and stained with hematoxylin and eosin (Annexure E). ZN and modified ZN 
stains were performed on all the bone marrow trephine biopsies to identify the presence 
of AFB’s (Annexures F & G). In some cases ZN stains were already performed during 
the initial assessment of the bone marrow, and the rest were performed subsequently as 
part of the study. Grocotts methenamine silver or periodic acid-schiff stains for fungal 
elements and other immunohistochemical stains were performed where appropriate.  
 
Blood and bone marrow mycobacterial cultures 
 
These were performed on request, at the time of the bone marrow biopsy. Peripheral 
blood or bone marrow aspirate material was inoculated at the bedside into Bactec Myco 
F/Lytic vials. These contain a Middlebrook liquid medium that supports the growth of 
mycobacteria, fungi, yeasts and anaerobic organisms. The Bactec vials were incubated at 
35 oC under 50% CO2 for 6 weeks in a Bactec automated blood culture incubator. ZN 
and Gram stains were performed on those with positive flags and sub-cultures were then 
performed in a Lowenstein-Jensen medium (Annexure H). Acid-fast organisms were 
identified by PCR as Mycobacterium tuberculosis, Mycobacterium avium complex or 
Mycobacterium other than tuberculosis. An in-house polymerase chain reaction (PCR) 
was used for the identification of Mycobacterium tuberculosis (Annexure I) and a 
Genotype Mycobacterium CM/AS 96 PCR kit for the rest (Mäkinen et al, 2006). Drug 















• Median values and ranges were determined for patient’s age, full blood count 
parameters and CD4 counts.  The median CD4 count of patients with bone 
marrow granulomata was determined. 
• The overall diagnostic yield of bone marrow biopsies and cultures were 
determined and the yield according to indications.  
• The diagnostic yields for bone marrow histological examination, bone marrow 
cultures and blood cultures were determined. 
• The mean turnaround times (duration between date sampled and date reported 
positive) were determined for bone marrow and blood culture results. 
• Fisher’s exact probability test was used to determine the significance of 
association between: the presence of poorly-formed granulomata and low CD4 
counts (< 100 x 106/L); well-formed granulomata and TB diagnoses; caseous 
necrosis and TB diagnoses; caseous necrosis and CD4 counts > 200 x 106/L. 
• The analysis to determine the predictive factors for diagnosis was performed 
using univariate analysis to assess the relationship between each predictor and 
diagnosis. The Stata 10 statistical software package (StataCorp, College Station, 
Texas) was used. Adjustments for age and sex were not included in the results 
because they were not identified as confounding factors (neither age nor sex 
predicted a new diagnosis on their own). 
• A Mann-Whitney U test was performed to determine the statistical significance 
between the presence and absence of any new diagnosis, new TB diagnosis and 
the following variables: age, gender, clinical indication, CD4 count, ARV 
treatment, white cell count, haemoglobin (Hb), platelet count, neutrophil count, 
lymphocyte count, monocyte count, eosinophil count, presence of granulomata 
and previous TB diagnosis. 
• All probability (p) values reported were two-sided and a value of < 0,05 was 












A.5 Research plan 
 
The project commenced in January 2007 and ran over 24 months. The first 18 months 
was dedicated to the retrospective identification of appropriate cases using bone marrow 
biopsy reports. The relevant information was retrieved from the laboratory records and 
the medical record department at Groote Schuur Hospital.   
 
During the last 6 months of the project ZN and Modified ZN stains were performed in 
the Anatomical Pathology Department on all cases included in the study. The stains 
were reviewed by Dr WA van Schalkwyk. 
 
Data analysis was performed after data collection. Conclusions were then drawn and any 
additional requirements were attended to. Dr WA van Schalkwyk was responsible for all 
data collection and performed the data analysis with the help of Dr Jo-Ann McLoughlin, 
Department of Public Health at the University of Cape Town, and Professor Nicolas 
Novitzky, Department of Haematology of the University of Cape Town. 
 
A.6 Operational budget   
 
ZN and Modified ZN stains 
Unit price:  R57.86 
Number of samples: 250 




Funding was provided by the NHLS K-project research fund and was obtained early in 
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The objectives of this literature review were to obtain the following background 
information: 
 
• The epidemiology of HIV in South Africa. 
• The frequency and causes of fever and cytopenias in patients with HIV. 
• The role of a bone marrow biopsy in the diagnosis of opportunistic infections and 
malignancy in HIV positive patients. 
• The utility of bone marrow biopsies, bone marrow cultures and blood cultures in 
the diagnosis of mycobacterial infections in HIV-positive patients in South 
Africa. 
 
B.2 Search strategy 
 
The literature search was initiated using the Pubmed Central digital archive. Further 
appropriate papers were identified by searching reference lists. Forty-nine relevant 
research papers were identified. An author-year referencing method was used. 
 
B.3 Quality criteria 
 
The keywords used for the Pubmed search included HIV and each of the following: 
South Africa, fever, pancytopenia, thrombocytopenia, anaemia, leucopenia, bone 
marrow biopsies, opportunistic infections and malignancy. Studies involving HIV 
positive patients who presented with fever and cytopenias were selected. Particular 
attention was given to studies performed in Southern Africa.  A distinction was made 













B.4 Summary of the literature 
 
Epidemiology of HIV in South Africa 
 
South Africa is the country with the largest number of HIV infections in the world.  
5,7 Million people were living with HIV in South Africa. (UNAIDS/WHO, 2008 [a]). 
Tuberculosis is the most common medical cause of death in HIV-infected adults. In 
some areas, two-thirds of patients with active TB are co-infected with HIV (Groenewald 
et al, 2005; Meya et al, 2007).  
 
The South African Department of Health has a comprehensive plan for the management, 
treatment, care and support of patients with HIV. The ARV treatment programme had 
enrolled approximately 370 000 people in the public sector by September 2007 with and 
an estimated 120 000 people in the private sector (UNAIDS WHO, 2008 [b]). 
 
Frequency and causes of fever and cytopenias in patients with HIV 
 
HIV-patients frequently present with PUO and peripheral cytopenias. A study performed 
by Adewuyi et al (1999) described the haematological features of HIV infection in adult 
Zimbabweans.  Cytopenias were frequent (47,5% of adults with HIV infection) and the 
most common abnormalities were lymphopenia (31,5%), anaemia (30,8%), neutropenia 
(29,6%), thrombocytopenia (24,7%), eosinophilia (23,5%) and leucopenia (11,7%). 
There was a lack of association between the severity of the haematological abnormalities 
and the clinical stage of the disease. 
 
 
Fever and cytopenias are often caused by disseminated opportunistic infections and 
malignancy (Armstrong et al, 1999; Santos et al, 2004; Tanaka et al, 2006). 
Suppression of the bone marrow directly by HIV or by its viral proteins, as well as 
indirect factors relating to immune and cytokine dysregulation, are also responsible for 











is a rare occurrence. CD34+ stem cells express low levels of the receptors and co-
receptors (CD4, CXCR-4 and CCR-5) necessary to permit HIV infection, making them 
relatively resistant to direct infection (Volberding et al, 2004). It appears more likely 
that cytokines such as interferon gamma (IFN-γ), tumour necrosis factor alpha (TNF-α) 
and interleukin-1 (IL-1) are responsible for marrow suppression and cytopenias. These 
cytokines are released by HIV infected mononuclear-macrophage cells and activated 
lymphocytes and induce significant bone marrow dysfunction and even progenitor cell 
death (Levine et al, 2001). Haemopoietic progenitor cells derived from bone marrows of 
HIV-patients have been reported to undergo increased apoptosis. TNF-α increases the 
expression of the Fas-receptor (Fas-R) on CD34+ cells. Increased levels of Fas-ligand 
(Fas-L), produced by activated T-cells result in increased apoptosis of haematopoietic 
progenitor cells through the Fas-L/Fas-R pathway. Activation of caspase 1, caspase 3 
and capase 8 appear to be important activators of several effector proteins in this 
pathway (Sloand et al, 2000). Although marrow stromal function has been examined, 
and susceptibility of stromal cells to HIV infection has been documented, actual 
infection of the stroma is a relatively rare event. Stromal function appears to play only a 
minor role in the pathophysiology of marrow dysfunction in HIV (Sloand, 2005).  
 
An association between HIV and thrombocytopenia was first described in 1982. The 
most common cause of this complication is ITP, which occurs in 30% or more of patient 
with HIV. While slightly more prevalent in those with advanced disease, ITP typically 
arises early in the course of HIV infection and can be seen before other manifestations of 
AIDS (Volberading et al, 2003). Defective megakaryopoiesis may also contribute to 
thrombocytopenia, particularly in patients with advanced disease. Megakaryocytes can 
be infected with certain strains of HIV, some of which can be cytopathic for the 
megakaryocytes (Sloand, 2005). 
The most frequent cause of anaemia in HIV-infected patients is Anaemia of Chronic 
Disease (Volberding et al, 2003). Cytokines such as IL-1, TNF and interferons play an 
important role in impairing erythropoietin response by reducing concentrations of 
marrow progenitors and erythroid colonies, and effecting abnormalities of reticulo-











patients with HIV is medication (Sloand et al, 2005). Zidovudine (AZT) is frequently 
associated with significant anaemia due to inhibition of thymidine kinase and 
deoxyribonucleic acid (DNA) chain termination. It inhibits in vitro erythroid colony 
formation in a dose-dependent manner. Severe anaemia can be seen in 24% of those who 
receive AZT 1500 mg daily, while neutropenia and thrombocytopenia are less common 
(Volberding et al, 2003). Haematologic toxicity is less frequently seen with other 
nucleoside analogs, such as Lamivudine (3TC) and Stavudine (d4T). The protease 
inhibitors have little or no effect on haemopoiesis (Sloand et al, 2005). Trimethoprim-
sulfamethoxazole (Bactrim®), an antibiotic commonly used for the prevention of 
Pneumocystis pneumonia (PCP), is associated with a high rate of side effects, including 
fever, rash and pancytopenia. In patients with poor nutritional status and in combination 
with other predisposing factors, the drug can cause megaloblastic anaemia, leucopenia 
and thrombocytopenia. Bone marrow suppression, seemingly unrelated to folate 
deficiency, is a frequent side effect of Bactrim® (Watera et al, 2007). Treatment of 
cytomegalovirus (CMV) infection with parenteral ganciclovir (GCV) may result in 
significant myelosuppression leading to leucopenia and thrombocytopenia after the 
second week of therapy. Oral GCV appears to have similar haematological effects. The 
antifungal agent amphotericin B is also frequently associated with myelosuppression. In 
addition to direct effects on the bone marrow, amphotericin renal toxicity may lead to 
diminished erythropoietin production (Sloand, 2005).  
 
A significant increase in white cell count, neutrophils and platelets, in addition to CD4+ 
T-cells, is seen in patients beginning HAART, with a simultaneous decline in plasma 
HIV ribonucleic acid (RNA) levels. The basis for these improvements is most likely due 
to the reversal of inhibitory effects of HIV replication. HIV protease inhibitors may have 
a direct effect on haematopoietic cells by inhibition of caspase 1, resulting in a reduced 














The role of a bone marrow biopsy in the diagnosis of opportunistic infections and 
malignancy in HIV positive patients 
 
Bone marrow biopsies are often used to investigate fever and cytopenias in patients with 
HIV, with reported diagnostic yields ranging from 27% to 42% in different studies. 
(Luther et al, 2000; Pacios et al, 2004; Tanaka et al, 2006). Karstaedt et al, 2001, 
retrospectively reviewed bone marrow biopsies performed on HIV-patients at Chris 





One of the most frequent reasons for performing a bone marrow biopsy in these patients 
is to diagnose opportunistic infections. Microbiologic cultures may be performed on 
bone marrow aspirate samples and histological examination of the trephine biopsy may 
identify morphological features of a disseminated infection, such as granuloma 
formation. Micro-organisms may be demonstrated by special staining techniques or 
direct microscopy. A variety of opportunistic infections can be identified in this way 
including Mycobacterium tuberculosis, Mycobacterium avium complex, Toxoplasma 
gondii, Histoplasma capsulatum and Cryptococcus neoformans (Jagadha et al, 1985; 
Karcher et al, 1990; Nichols et al, 1991; Luther et al, 2000; Akpek et al, 2001). Because 
the histological bone marrow examination result may be available within days and 
mycobacterial cultures take 3 to 6 weeks, a considerably quicker diagnosis of 
disseminated mycobacterial infections can be made on histology. (Bishburg et al, 1986; 
Ciaudo et al, 1994; Engels et al, 1995; Kilby et al, 1998). This allows the rapid 
institution of antimicrobial therapy which reduces morbidity and mortality (Nichols et 
al, 1991; Benit et al, 1997; Hussong et al, 1998; Karstaedt et al, 2001). 
 
Granuloma formation is the typical inflammatory response seen in tissues infected with 
mycobacterial or fungal organisms. In the setting of immunodeficiency such as AIDS, 











Some authors report granulomata to be less frequent with a low correlation between the 
presence of granulomata in the bone marrow and the detection of organisms by special 
stains or culture (Bishburg et al, 1986).  This was confirmed by Marques et al (2000) 
who evaluated the efficacy of blood cultures, bone marrow cultures and histological 
examination of the bone marrow for predicting the presence of infection. Bone marrow 
granulomata were seen in only 9 of 27 patients with mycobacterial infections and AFB’s 
were seen in only 7.  In contrast, other groups have found a high percentage of bone 
marrow granulomata in patients with disseminated mycobacterial infections (Karcher et 
al, 1990; Nichols et al, 1991; Ciaudo et al, 1994; Luther et al, 2000). Karstaedt et al 
(2001) found bone marrow granulomata in 93% of patients with TB. They found, 
however, that the use of empiric anti-TB therapy on the basis of bone marrow 
granulomata was microbiologically appropriate in only 41% of patients with non-
caseous granulomata. Empirical anti-tuberculosis therapy is still frequently 
recommended in TB-predominant geographical regions such as South Africa, on the 
basis of the presence of granulomata in the bone marrow.       
 
Bone marrow cultures are useful to confirm the presence of micro-organisms, as well as 
for identification purposes and to determine their antibiotic susceptibility (Ciaudo et al, 
1994). The absence of AFB’s or granulomata in the bone marrow trephine biopsy does 
not exclude the eventual growth of organisms in bone marrow cultures (Prego et al, 
1990). Several studies have shown that bone marrow cultures are more sensitive than the 
bone marrow histological examination for the diagnosis of disseminated mycobacterial 
and fungal infections (Benit et al, 1997; Ker et al, 2002).  
 
Mycobacterial blood cultures are underutilized in South African hospitals and are not 
used in the routine investigation of pyrexial patients or in patients suspected of having 
disseminated mycobacterial infections. Sputum microscopy is preferred. This is likely 
due to a lack of availability of mycolytic vials and financial constraints as the cost of a 
mycobacterial blood culture is approximately three hundred and twenty five rand; 












 A study performed by Von Gottbert et al (2001) in Johannesburg found that 
bacteraemia with Mycobacterium tuberculosis was detected in 28% of HIV-infected 
patients with suspected TB, including those with localized pulmonary disease on initial 
clinical assessment. AFB’s were detected on sputum microscopy in 42% of these 
patients and sputum cultures were positive in 57%. They concluded that bacteraemia 
with Mycobacterium tuberculosis was common in HIV-infected patients with suspected 
TB. Blood cultures were also useful in distinguishing disseminated Mycobacterium 
avium from Mycobacterium tuberculosis infections.  
 
Blood and bone marrow cultures have been shown to be equivalent testing modalities for 
the diagnosis of disseminated mycobacterial and fungal infections in AIDS-patients, 
with a yield of approximately 20% for disseminated mycobacterial infections and 8% for 
disseminated fungal infections (Marques et al, 2000). Their combined use provides a 
higher diagnostic yield (Northfelt et al, 1991; Ker et al, 2002; Pacios et al, 2004). 
Several authors have recommended that blood cultures should be the first step in the 
routine evaluation of AIDS patients when disseminated mycobacterial or fungal 
infections are suspected. They suggest that an early bone marrow biopsy should be 
reserved for extremely ill patients in whom a more aggressive approach is needed 
(Keiser et al, 1997; Kilby et al, 1998; Marques et al, 2000). Other authors feel that, 
because of the additional diagnostic yield of a biopsy, both peripheral blood and bone 
marrow cultures should be performed early in the evaluation of this patient group. 
(Bishburg et al, 1986; Fernandez-Aviles et al, 1995; Benit et al, 1997; Luther et al, 




NHL occurs with a 60 – 200 fold increased frequency in HIV-positive compared with 
HIV-negative patients, particularly in the pre–HAART era. Primary CNS lymphoma and 
Burkitt lymphoma are increased approximately 1000 times in comparison with the 
general population. In 1985 the United States Centre for Disease Control and Prevention 











risk of NHL has declined dramatically and is consistent with improved CD4 counts. 
Burkitt lymphoma however, showed no evidence of decline.  Because HAART is 
associated with enhanced survival and a 75% decrease in mortality, lymphomas now 
contribute to a greater percentage of first AIDS-defining illness (Beral et al, 1991; 
Levine et al, 1993; Cote et al, 1997; Swerdlow et al, 2008). Before the era of HAART, 
the incidence of HL in HIV-patients was increased 8 fold (Hussong et al, 1998) and 
there has been an unexpected increase in its incidence since the advent of HAART 
therapy. This is possibly related to improvements in CD4 counts (Beral et al, 1991; 
Swerdlow et al, 2008). An essential feature of HL is the non-neoplastic milieu of 
reactive cells which surround the Hodgkin-Reed Sternberg (H-RS) cells in the tumour 
mass. The recruitment of inflammatory cells may provide essential feedback signals that 
stimulate proliferation or inhibit apoptosis of H-RS cells. HL incidence may decline in 
severely immunosuppressed HIV-patients because the malignant H-RS cells are not able 
to recruit lymphocytes and histiocytes required for their survival (Biggar et al, 2006). In 
contrast to the low incidence of bone marrow involvement by HL in immune-competent 
patients, bone marrow involvement is more frequently seen in HIV patients and the bone 
marrow may also be the site of primary diagnosis (Fend and Kremer, 2007).  
 
A bone marrow biopsy is often performed to investigate for lymphoma in HIV-positive 
patients with only fever and cytopenias and no lymphadenopathy nor 
hepatosplenomegaly. However, high-grade NHL has been reported to less frequently 
involve the bone marrow which implies a low sensitivity of this investigation as a 
diagnostic tool (Malyangu et al, 2000; Swerdlow et al, 2008). Levine et al (2002) 
retrospectively compared staging bone marrow biopsies performed on HIV-patients with 
indolent B-cell lymphomas to those with high-grade NHL. They found bone marrow 
involvement to be significantly more common in indolent NHL cases (50%) than high-
grade NHL cases (17%). Santos et al (2004) found bone marrow biopsies unhelpful in 
the diagnosis of high-grade NHL in patients with AIDS. Another study in Zimbabwe 













Predictors of a Positive Bone Marrow Examination 
 
Several authors have previously compared the clinical and laboratory findings of HIV-
patients with diagnostic versus non-diagnostic bone marrow biopsies in an attempt to 
identify predictive features. Some concluded that a bone marrow biopsy is most 
diagnostic in patients where fever and cytopenias co-exist than fever or cytopenias alone 
(Ciaudo et al, 1994; Brook et al, 1997; Karstaedt et al, 2001; Llewelyn et al, 2005; 
Tanaka et al, 2006).  Keiser et al  (1997) reported that a CD4+ T-lymphocyte count < 50 
x 106/L and a haematocrit < 25% were predictive of a diagnostic bone marrow biopsy, 
while others found the bone marrow was most likely to yield a diagnosis if the 
haematocrit was <30% (Luther et al, 2000). 
 
The utility of bone marrow biopsies, bone marrow cultures and mycobacterial blood 
cultures in HIV positive patients in South Africa 
 
Karstaedt et al (2001) retrospectively reviewed a consecutive case series of 257 adults 
with HIV infection who had undergone a bone marrow examination at Chris Hani 
Baragwanath Hospital between January 1996 and December 1997 to assess the 
diagnostic usefulness of bone marrow biopsy and culture. They concluded that the bone 
marrow examination gave a unique diagnosis in 24% of patients, which was a high 
proportion compared to other studies. The most common new diagnosis made was 
disseminated mycobacterial infections. Predictors identified for a positive bone marrow 
biopsy were wasting, oral thrush, leucopenia and low CD4 count (< 100 x 106/L). A 
possible explanation for the high yield was that blood cultures for mycobacterial disease 
were not available for routine use in South African hospitals at that time. They could 
therefore not be used as an early investigation before a bone marrow biopsy was 
performed. They concluded that expanding access to mycobacterial blood culture 
technology at primary care level would limit the number of bone marrow examinations 
required. They noted that at that stage, most South African HIV-infected patients did not 
have access to bone marrow biopsies, blood cultures nor CD4 counts. The situation has 











counts and HAART, however access to bone marrow biopsies and blood cultures for 
most patients remains poor.  
 
B.5 Identification of needs for further research 
 
The spectrum of opportunistic disease in HIV-patients varies among different regions of 
the world and it is important to identify local patterns (Kaplan et al, 1996). Most 
published research in this area has been done outside of South Africa. There have been 
no studies in the Western Cape to examine the utility of bone marrow biopsies in HIV-
patients. Published work was done before the rollout of HAART started in the public 
sector in March 2004. Ongoing management of opportunistic and HIV-related illnesses 
is required in HIV-patients; either prior to starting HAART, during treatment or after 
treatment has failed. Research is required for the development of cost-effective ways to 
diagnose and treat opportunistic disease in HIV-infected individuals in South Africa and 
to predict the changing requirements for this care as the rollout of HAART becomes 
more established.  
 
 
The Western Cape has the highest annual TB notification rate (1000/100 000 
individuals) (Meya et al, 2007). It is crital to provide adequate and effective care to co-
infected individuals. Early detection of multidrug resistant TB in our community is a 
priority and it is important to determine the role of blood cultures, bone marrow cultures 
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Introduction: A bone marrow biopsy is frequently requested in the work-up of patients 
with Human Immunodeficiency Virus (HIV) infection who present with fever and/or 
cytopenias in the search for opportunistic infections and malignancies. 
Methods: This is a retrospective review of the results of consecutive bone marrow 
biopsies performed at our institution over a three year period on HIV positive patients 
for the investigation of fever and cytopenias. Clinical data, haematological parameters, 
morphology of bone marrow biopsy, Ziehl-Neelsen staining and microbiological culture 
results were analyzed.  The aim of the study was to determine the diagnostic yield of this 
investigation.  
Results: Sixty three males and 84 female patients were included for the analysis. 
Indications for bone marrow biopsies were cytopenias in 79% (n= 115), pyrexia of 
unknown origin (PUO) alone in 1% (n= 2) and both PUO and cytopenias in 20% (n= 
30). The bone marrow biopsy gave a high diagnostic yield of 47% (70 patients) and a 
unique diagnosis in 33% (49 patients). Immune thrombocytopenic purpura and 
disseminated mycobacterial infections were the most common unique diagnoses made 
(14% each), followed by malignancies (4%).  In this cohort, 4 cases of primary bone 
marrow involvement by Hodgkin lymphoma and 1 case of involvement by non-Hodgkin 
lymphoma were diagnosed. Cytopenias and granulomata were significantly associated 
with lower CD4 counts (p= 0,01). Granulomata in the marrow was significantly 
associated with disseminated tuberculosis (p= 0,001), and past diagnosis of tuberculosis.  
Conclusions: We conclude that in our study group bone marrow biopsy was a useful 












South Africa is currently experiencing one of the most severe Acquired Immune 
Deficiency Syndrome (AIDS) epidemics in the world. By the end of 2007 5,7 million 
people were living with the Human Immunodeficiency Virus (HIV) (UNAIDS/WHO, 
2008 [a]). Co-infection with tuberculosis (TB) is the most common cause of death in this 
population group. In some areas of South Africa, two-thirds of patients with active TB 
are HIV positive (Groenewald et al, 2005; Meya et al, 2007).  The South African 
Department of Health currently has a comprehensive HIV treatment plan. 
HIV positive patients frequently present with pyrexia of unknown origin (PUO) and 
peripheral blood cytopenias, which may be caused by dysregulated immune system,  co-
infection with TB, disseminated opportunistic infections, malignancy, drugs or other 
haematological conditions. Methods of identifying a disseminated infection with TB 
include microbiological cultures of the peripheral blood or bone marrow aspirate, Ziehl-
Neelsen (ZN) staining of the bone marrow aspirate, histological examination of the 
trephine biopsy and the demonstration of micro-organisms by special staining 
techniques. A bone marrow biopsy may be a useful analytical tool in some of these 
patients, with the reported diagnostic yield ranging from 27% to 42% (Engels et al, 
1995; Brook et al, 1997; Luther et al, 2000; Pacios et al, 2004; Tanaka et al, 2006). 
Because morphological examination is performed within days while mycobacterial 
cultures take 3 to 6 weeks to grow, a considerably faster diagnosis of disseminated 
mycobacterial infections may be made on histological examination (Bishburg et al, 
1986; Kilby et al, 1998; Luther et al, 2000). Bone marrow biopsies are often performed 
for the exclusion of lymphoma in HIV patients. 
At our institution we are currently experiencing a high demand for bone marrow 
biopsies in this patient group. The Western Cape has the highest proportion of HIV-
infected individuals taking antiretroviral treatment in the country (UNAIDS/WHO, 2008 
[b]). Despite the stabilization of HIV prevalence in the Cape Town Metro region, the 
2007 South African HIV and Syphilis Prevalence Survey showed a notable increase in 
HIV prevalence among antenatal clinic attendees in rural districts of the province 











rate (1000/100 000 individuals) and early detection of multidrug resistant TB in our 
community is a priority (Meya et al, 2007). In the background of limited resources, 
questions are raised regarding the cost-effectiveness of bone marrow biopsies in HIV 
patients and the possibility of selecting patients in whom this investigation would be 
most useful. 
 
The spectrum of opportunistic disease in HIV-patients varies among different regions of 
the world and it is important to identify local patterns (Kaplan et al, 1996). Most 
published research in this area has been done outside of South Africa. There have been 
no studies in the Western Cape to examine the utility of bone marrow biopsies in HIV-
patients. Published work was done before the rollout of HAART started in the public 
sector in March 2004. Ongoing management of opportunistic and HIV-related illnesses 
is required in HIV-patients; either prior to starting HAART, during treatment or after 
treatment has failed. Research is required for the development of cost-effective ways to 
diagnose and treat opportunistic disease in HIV-infected individuals in South Africa and 
to predict the changing requirements for this care as the rollout of HAART becomes 
more established.  
 
Groote Schuur Hospital serves as a tertiary referral centre in the Western Cape, South 
Africa. HIV prevalence among antenatal clinic attendees in the region is approximately 
15,1% (UNAIDS/WHO, 2008 [d]). As a 936 bed, public sector university hospital, there 
are approximately 44 000 inpatient admissions and 575 000 outpatient attendances per 
year, with specialized Infectious Diseases and Anti-Retroviral clinics. This study 
retrospectively evaluated the diagnostic yield of consecutive bone marrow biopsy results 
on HIV-positive patients reviewed retrospectively for the period January 2004 to 
December 2007. The study was approved by the Research Ethics Committee of the 


















Inclusion criteria were as follows:  HIV positive (as indicated by the clinician on the 
bone marrow request form) adults ≥ 18 years of age who underwent bone marrow 
biopsies for the investigation of fever, fever and cytopenias or cytopenias alone. Fever 
was defined as an armpit temperature greater than 38oC. Anaemia was defined as a 
haemoglobin concentration < 13 g/dL for men and < 12 g/dL for women, leucopenia as a 
total white cell count < 4 x 109/L and thrombocytopenia as a platelet count < 137 x 109/L 
for men and < 178 x 109/L for women. The following specimens were excluded: 
biopsies on patients below 18 years of age, biopsies done solely to stage previously 
diagnosed lymphoma and follow-up bone marrow biopsies for previously diagnosed 
haematological diseases. Bone marrow specimens referred to Groote Schuur Hospital 
from other centres were not included in the study. 
 
A standardized data-collection sheet was used to record the following information: 
indication for bone marrow biopsy, patient characteristics, prior diagnoses of 
mycobacterial infection or malignancy, antiretroviral therapy, CD4 lymphocyte count, 
peripheral blood counts, mycobacterial bone marrow aspirate and blood culture results, 
final diagnosis made by bone marrow biopsy and resulting changes made to the patient’s 
management. Files were sourced according to the laboratory specimen numbers. Clinical 
data was obtained from the patient’s Groote Schuur Hospital folders which were drawn 
from archives using the patient hospital numbers. The patient’s name and personal 
details were not recorded. Each case was then assigned a random number which was 
used during statistical analysis 
 
Posterior iliac crest bone marrow samples were collected and processed according to 
standard protocols. Samples were fixed in Zenker’s solution and decalcified in formic 
acid. Three-micrometer sections were cut and stained with hematoxylin and eosin. Both 
ZN and modified ZN stains for acid-fast bacilli (AFB’s) were routinely performed in all 
cases and were microscopically examined throughout the entire area of the sections and 











methenamine silver or periodic acid-schiff stains for fungal elements and other 
immunohistochemical stains were performed. Peripheral blood and bone marrow 
aspirate material was inoculated at the bedside into Bactec Myco F/Lytic vials which 
were incubated at 35oC under 50% CO2 for 6 weeks. An in-house PCR was used for the 
identification of Mycobacterium tuberculosis while for other mycobacterial organisms a 
Genotype Mycobacterium CM/AS 96 PCR kit (Mäkinen et al, 2006) was employed. 
Mean turnaround times (duration between date sampled and date reported positive) for 
bone marrow and blood culture results were determined. Absolute CD4 lymphocyte 





Descriptive statistics were employed to define the study population.  Overall diagnostic 
yield, yield according to indication, diagnostic yield for bone marrow histological 
examination, diagnostic yields for bone marrow and blood cultures were determined.  
Analysis was performed to establish the predictive factors for a diagnosis. A p 
(probability) value of < 0,05 was considered statistically significant. Univariate analysis 
was used to assess the relationship between each predictor and diagnosis. Non 
parametric statistics were applied to determine possible relationship between unique 
diagnosis (yes, no), diagnosis of tuberculosis (yes, no) and clinical parameters.  Age, 
gender, fever, CD4 count, ARV therapy, prior diagnosis of TB, current TB treatment, 
leucopenia, anaemia, thrombocytopenia, neutropenia, lymphopenia and granulomata  
were analyzed as possible predictors. Analysis was performed using Stata 10 statistical 





















The review of the records of 147 patients (63 males; 43% and 84 females; 57%) was 
included in this study. A summary of the clinical and haematological parameters at the 
time of the bone marrow biopsy are shown in tables I and II. Indications for the bone 
marrow biopsies are summarized in table III. Most commonly patients presented with 
anaemia and thrombocytopenia (43%), followed by a pancytopenia (31%), anaemia 
alone (15%), thrombocytopenia alone (5%) and anaemia with a leucopenia (5%). One 
hundred and twenty seven patients (86%) had a CD4 count performed and in 115 (91%) 
the values were < 200 x 106/L. The median CD4 count was 73 x 106/L (range 1-697 x 
106/L). Thirty eight patients had prior diagnoses of mycobacterial infections and 30 were 
already on anti-TB treatment. Thirty-two (22%) patients were on antiretroviral therapy, 
but their adherence to therapy was not well documented. The CD4 count was graded into 
≥ 200, 100-199, 50-99 and < 50 x 106/L. Reduced CD4 count grades were significantly 
related to leucopenia (p= 0,02), thrombocytopenia (p= 0,01), lymphopenia (p= 0,001), 
monocytopenia (p= 0,01) and the finding of granulomata in the marrow (p= 0,001). 
There was also a significant correlation between severity of reduction of CD4 count and 
the number of haematopoietic lineages reduced (single line, bicytopenia and 
pancytopenia) (p= 0,01). Fever as an indication for the procedure was only significantly 
associated with lower median lymphocyte count (p= 0,02) but did not result in a new 
diagnosis. 
 
Bone Marrow Morphological Examination 
 
A diagnosis was made by bone marrow biopsy in 44% (n= 65) and a new diagnosis was 
made in 28% (n= 41). Granuloma formation was reported in 33% (n= 49) and in 37 of 
these a specific cause for granuloma formation was found. Granulomata in the marrow 











counts (see Table IV).  The finding of a granuloma was significantly associated with a 
new diagnosis of TB (p= 0,0001).  
 
Two patients were already diagnosed with disseminated cryptococcal infections on 
cerebrospinal fluid samples. Both had well-defined epithelioid granulomata and fungal 
stains showed the presence of cryptococci, but bone marrow cultures were negative. 
Fungal stains were performed on 30 other cases, but none of these were positive. 
Malignancy was demonstrated in 6 trephine biopsy specimens, and in all of these the 
diagnoses were confirmed by immunohistochemical stains. 
  
Bone Marrow Microbiological Culture 
 
Microbiological cultures for TB were performed on bone marrow aspirates in 84% (n= 
124) patients and provided a unique diagnosis in 5% (n= 8). In 15 of the 18 (83%) 
positive cultures, bone marrow granulomata were seen and in 8 (44%) cases AFB’s were 
demonstrated by ZN stains. Mycobacterium tuberculosis was isolated in 13 cases, 
Mycobacterium avium complex in 4 cases and an unidentifiable mycobacterium in 1 
culture. The mean time to positive growth for Mycobacterium tuberculosis bone marrow 
cultures was 700 hours (range 385-980 hours) and 582 hours (33-790 hours) for 




Mycolytic blood cultures were performed on 17 (11%) patients. Mycobacterial 
organisms were isolated in seven cases: 6 Mycobacterium tuberculosis and 1 
Mycobacterium avium complex. The mean time to positivity for Mycobacterium 
tuberculosis blood cultures was 471 hours (range 375-656 hours) and the one case of 
Mycobacterium avium complex showed a positive result after 265 hours. Two other 
cases that had cultures performed had no morphological evidence to suggest 














A specific diagnosis was made by bone marrow biopsy or culture in 70 patients, which 
gave the procedure an overall diagnostic yield of 47%.  In 21 of these patients the same 
diagnoses were made by alternative diagnostic modalities. Following testing of the bone 
marrow as a diagnostic procedure, unique diagnoses, which resulted in a change of 
patient management, were thus made in 49 cases (33%). The diagnostic yield according 
to indication was as follow: PUO and cytopenias led to a new diagnosis in 13 cases 
(9%), cytopenias alone was responsible for a new diagnosis in 36 cases (25%). Table V 
summarizes the diagnostic yield of the bone marrow biopsies. 
 
Predictors of a Positive Bone Marrow Examination 
 
The bone marrow examination was helpful (see Table VI) in leading to a new diagnosis 
in patients with lower (than median) CD4 counts (p= 0. 02); Hb (p= 0,01); platelet 
counts (p= 0,01); neutrophil counts (p= 0,02) and if they had had TB in the past (p= 
0,01).  To address the utility of bone marrow biopsy for diagnosis of disseminated 
mycobacterial infections, analysis was repeated using only tuberculosis as the outcome 
variable. Man-Whitney U test (see Table VII) indicated that diagnosis of TB was 
significantly more likely in patients with lower (than median) platelet count (p= 0,04), 
finding bone marrow granulomata (p= 0,0001), previous diagnosis of TB (p= 0,01) and 




Fever and cytopenias are frequent and significant problems in patients infected with 
HIV, so it is important to establish as quickly as possible their etiological causes. 
Consequently, we undertook this retrospective analysis to evaluate the diagnostic utility 
of the bone marrow biopsy as a diagnostic tool in this patient group. The procedure led 
to important new diagnoses of auto-immune disease, opportunistic infections, 












When comparing these conclusions with earlier similar studies, our diagnostic yield falls 
within the previously reported ranges of 27% to 42%. (Engels et al, 1995; Brook et al, 
1997; Benit et al, 1997; Luther et al, 2000; Pacios et al, 2004; Tanaka et al, 2006). In 
addition, in the pre-HAART era in South Africa, Karstaedt et al (2001) performed a 
similar review at Chris Hani Baragwanath Hospital in Johannesburg. In this study, bone 
marrow examination was found to give a unique diagnosis in 24% of patients and the 
highest yield was obtained in patients with advanced HIV; defined as CD4 count < 100 x 
106/L. Although our study was performed during the roll-out of HAART in South Africa 
(initiated March 2004), only 22% (n= 32) of our cohort were on this therapy.  Therefore 
the current study does not reflect the full impact of HAART; whilst the need for 
HAART treatment in appropriate patients is highlighted. 
 
Twenty one patients (14%) were diagnosed with immune thombocytopenic purpura 
(ITP), which added to the high diagnostic yield. The association between HIV and ITP is 
well described and occurs with an incidence of 5% - 30% (Liebman, 2008). While 
slightly more prevalent in those with advanced disease, ITP typically arises early in the 
course of HIV infection and is often seen before other manifestations of AIDS 
(Volberading et al, 2003). In our cohort, the median presentation platelet count of 
patients with ITP was 15 x 109/L (range 6 – 86 x 109/L) and their median CD4 count 
was 198 x 106/L (range 18 – 561 x 106/L). The majority (68%; n= 14) presented with 
anaemia and thrombocytopenia, followed by isolated thrombocytopenia in 32% (n= 7) 
and none with pancytopenia or PUO. Bone marrow biopsy confirmed the diagnosis of 
ITP in all these patients and no additional pathology was found. This supports the 
argument that if the history, physical examination, blood count and blood film 
examination are consistent with the diagnosis of ITP, the bone marrow biopsy is 
unnecessary (Provan et al, 2003). 
 
The second most common new diagnosis made was disseminated mycobacterial 
infection found in 20 (14%). In view of the fact that TB is the major cause of death in 











present with fever and cytopenias. The early detection of multidrug resistant TB in our 
community is a priority. Another 38 (26%) patients had already been diagnosed with 
mycobacterial infections before the bone marrow biopsy was performed, and most of 
them were already on TB treatment. Evidence of granulomatous inflammation was 
found in 21 (55%) of these patients and 5 (13%) had positive ZN stains. Bone marrow 
cultures were performed in 30, of which 5 (17%) were positive. Evidence of active TB 
reflected either that TB therapy was only recently started,  non-adherence to treatment or 
resistant disease, which confirmed the highly relevant diagnostic role of a bone marrow 
biopsy in patients already on TB treatment who presents with fever and cytopenias.  
 
Of the twenty new cases with a mycobacterial infection, the diagnosis was based on 
identification of bone marrow AFB’s alone in 7 (35%) and on the result of a bone 
marrow culture alone in another 7 (35%) cases. In another 6 (30%) cases both these 
investigations were positive. The performance of bone marrow cultures increased the 
diagnostic yield and confirmed the diagnosis.  In two patients AFB’s were demonstrated 
by ZN stains without morphological evidence of granulomatous inflammation in the 
marrow. The mean time to positivity for mycobacterial cultures were several hundred 
hours (29 days), while a much quicker diagnosis was made on the trephine biopsy by ZN 
stains. Thus, both ZN stains and bone marrow aspirate cultures should routinely be 
performed whenever a mycobacterial infection is suspected. As only 6% of patients had 
mycobacterial blood cultures performed, an accurate comparison between the diagnostic 
yield and turnaround times of mycobacterial blood versus bone marrow cultures could 
not be made. However, blood cultures provided a unique diagnosis in two patients in 
whom no AFB’s could be demonstrated in the trephine biopsy and who had negative 
bone marrow cultures. Previous studies have shown mycobacterial blood cultures to be 
an equivalent testing modality to bone marrow cultures for the diagnosis of disseminated 
tuberculoses and fungal infections in AIDS-patients. Their combined use also led to a 
higher diagnostic yield (Northfelt et al, 1991; Ker et al, 2002; Pacios et al, 2004).   
 
Evidence of granulomatous inflammation was frequent (33%) and in the majority of 











identification of AFB’s with ZN stains (30%), positive bone marrow/blood cultures 
(27%) or both (19%). In 8 (24%) patients the diagnosis could not be confirmed, but the 
diagnosis was considered as highly likely by the reporting pathologist.  Since fungal 
infections are much less frequently seen than mycobacteria in AIDS patients in South 
Africa, routine cytochemical stains for fungi and yeasts were not performed on the 
trephine biopsies in this study (Groenewald et al, 2005).   
  
Because staging bone marrow biopsies on patients with previously diagnosed 
lymphomas were excluded from the study, very few malignancies were identified. This 
confirms the relatively low utility of a bone marrow biopsy as the primary diagnostic 
procedure for non-Hodgkin lymphoma in HIV patients with fever and/or cytopenias and 
no other systemic features to suggest lymphoma. Nevertheless, bone marrow 
involvement is seen with increased frequency in HIV patients with Hodgkin lymphoma 
(HL) and is confirmed in our study as four (3%) patients who had no other features to 
suggest malignancy were found to have primary bone marrow HL.  
 
Several authors have previously compared the clinical and laboratory findings of HIV-
patients with diagnostic versus non-diagnostic bone marrow biopsies, in an attempt to 
identify predictive features. Some concluded that a bone marrow biopsy is most 
diagnostic in patients where fever and cytopenias co-exist than fever or cytopenias alone 
(Ciaudo et al, 1994; Brook et al, 1997; Karstaedt et al, 2001; Llewelyn et al, 2005; 
Tanaka et al, 2006). We could not confirm this observation in our cohort. In our study 
group a diagnostic marrow was associated with a lower (than median) CD4 count (p= 
0,02), Hb (p= 0,01), platelet count (p= 0,01), neutrophil count (p= 0,02) and if they had 
had TB in the past (p= 0,01). Keiser et al (1997) reported that a CD4+ T-lymphocyte 
count < 50 x 106/L and a haematocrit < 25% were predictive of a diagnostic BM biopsy, 
while others found the bone marrow most likely to yield a diagnosis if the haematocrit is 
< 30% (Luther et al, 2000). This is not surprising as most opportunistic infections occur 













Thus we conclude that in patients with pure thrombocytopenia without other cytopenias 
or fever (0/7), the bone marrow biopsy did not yield a new diagnosis other than ITP. 
Thus in this group, the procedure could probably be omitted. However for those with 
other cytopenias and fever, it resulted in a new diagnosis in 28% of patients. Thirdly, it 
was a useful tool with a quick turnaround time and made a new diagnosis of tuberculosis 
in 20/147 individuals. In this group, all had anaemia and 17/20 had bi/pancytopenia. 
Bone marrow cultures for TB are recommended whenever disseminated TB is 
suspected. Lastly, the bone marrow biopsy also resulted in the new diagnosis of 
unsuspected malignancy (6/147). A weakness of this study is its retrospective nature and 
that the biopsies were performed solely at the clinicians request and no selection criteria 
were used. Another potential bias is the fact that Groote Schuur Hospital is a referral 
centre for specialist care and its patient population is unlikely to represent the general 











Table I. Clinical characteristics of the study population on presentation. 
 
Parameter       Value 
 
Age (years); median (range) 34 (18-62) 
Gender M/F 63/84 
ARV therapy; n (%) 32 (22%) 
Previous TB diagnosis: n (%) 38 (26%) 
Current TB treatment; n (%) 30 (20%) 
Previous diagnosis of malignancy; n (%) 0 
 
 
CD4 count (x 106/L); median (range)  73 (1-697) 
 < 50 (x 106/L) 54 (43%) 
 50-99 (x 106/L)  15 (15%) 
 100-199 (x 106/L)  18 (14%) 












































Leucocyte count (x 109/L); median (range) 4,3 (0,5-22,5) 
 < 2  28 (19%) 
 2, 0-2, 9  18 (12%) 
 3, 0-3, 9  18 (12%) 
Haemoglobin (g/dL); median (range) 7,8 (1,9-14,9) 
 < 6 32 (22%) 
 6, 0-9, 9 88 (60%) 
 10-12 (F) / 10-13 (M) 17 (12%) 
Platelet count (x 109/L); median (range) 70 (4-712) 
 < 50 54 (37%) 
50-99 43 (29%) 
100-178 (F) / 100-137 (M) 11 (8%) 
Neutrophil count (x 109/L); median (range) 2,9 (0,2-18,2) 
 < 0, 5 8 (5%) 
 0, 5-1, 4 25 (17%) 
 1, 5-2, 0 7 (5%) 
Monocyte count (x 109/L); median (range) 0,2 (0,0-2,3) 
Lymphocyte count (x 109/L); median (range) 0,65 (0,0-3,8) 
Eosinophil count (x 109/L); median (range) 0,01 (0,0-1,1)  
 
     












Table III. Indications for bone marrow biopsy. 
 
Indication:  Total Unique bone marrow diagnoses 
  n (%) n (%) 
 
Anaemia  12 (8%) 3   (6%) 
Anaemia and leucopenia  6   (4%) 0 
Anaemia and thrombocytopenia 51 (34%) 17 (35%) 
Thrombocytopenia  7   (5%) 7   (15%) 
Pancytopenia  39 (27%) 9   (18%) 
 
PUO alone  2   (1%) 0 
PUO and: 
    anaemia  7   (5%) 2   (4%)    
    anaemia and leucopenia  6   (4%) 4   (8%) 
    anaemia and thrombocytopenia 7   (5%) 3   (6%)  
    pancytopenia  9   (6%) 3   (6%) 


















Table IV. Clinical and haematological parameters associated with bone marrow 
granulomata (Fisher’s Exact Test). 
 
Parameter   No granulomata     Granulomata p value 
 n=98 n=49 
 
White cell count (x 109/L), median 4,9 3,5 0,001 
Haemoglobin (g/dL), median 7,7 7,3 0,2 
Platelet count (x 109/L), median 72 71 0,3 
Neutrophil count (x 109/L), median 3,4 2,3 0,02 
Monocyte count (x 109/L), median 0,3 0,2 0,04 
Lymphocyte count (x 109/L), median 0,8 0,5 0,1 
CD4 count (x 106/L), median 137 40,5 0,001 
Previous TB diagnosis 33 22 0,01 
Current TB therapy 28 19 0,2 


















Table V.  Summary of diagnostic bone marrow biopsies. 
 
Diagnoses Total diagnoses Unique diagnoses  
 70 (48%)   49 (33%)  
 
Infectious diseases: 
Disseminated mycobacterial infections  38 (26%)    20 (14%) 
Diagnosis based on: 
 - Trephine biopsy: 20 (13%)  7   (5%) 
 - Aspirate culture: 9   (6%)  6   (4%)  
 - Trephine biopsy and aspirate culture: 9   (6%)  7   (5%) 
Disseminated cryptococcal infections  2   (1,4%)  0 
 
Malignant diseases: 
Hodgkin Lymphoma  4   (2,7%)  4   (2,7%) 
Non-Hodgkin Lymphoma  1   (0,6%)  1   (0,6%) 
Metastatic Malignant Melanoma  1   (0,6%)  1   (0,6%) 
  
Other: 
Immune Thrombocytopenic Purpura  21 (14%)  21 (14%) 
Parvovirus-induced pure red cell aplasia  1   (0,6%)  0 
Drug-induced pure red cell aplasia  1   (0,6%)  1   (0,6%) 

















Table VI.  Predictors of a new diagnosis (Mann-Whitney U test). 
 
Predictor Rank Sum  Rank Sum  U* Z# p-value 
 No Yes 
 
Age 7177,000 3701,000 2326,000 -0,30818 0,76 
Gender 7472,500 3405,500 2180,500 0,90606 0,37 
CD4 count 4876,500 3251,500 1390,500 -2,20652 0,02 
ARV treatment 5911,500 2999,500 1918,500 0,39026 0,69 
Previous TB diagnosis 7747,000 2984,000 1759,000 2,55909 0,01 
Granulomata 7129,500 3748,500 2278,500 -0,50337 0,61 
White cell count 6721,000 4010,000  1968,000 -1,69323 0,09 
Haemoglobin 6516,500 4214,500 1763,500 -2,54044 0,01 
Platelet count 7751,500 2979,500 1754,500 2,57774 0,01 
Neutrophil count 5003,500 3252,500 1348,500 -2,41758 0,02 
Monocyte count 5387,500 2740,500 1732,500 -0,26904 0,79 
Lymphocyte count 5618,500 2637,500 1691,500 0,68611 0,49 
Eosinophil count 5515,500 2485,500 1624,500 0,61443 0,54 
 
 
* U value is the number of times observations in one sample precede observations in the other sample in the ranking. 















Table VII. Predictors of a new TB diagnosis (Mann-Whitney U test). 
 
Predictor Rank Sum  Rank Sum  U Z p-value 
 No Yes 
 
Age 9322,500 1555,500 1321,500 -0,00830 0,99 
Gender 9471,000 1407,000 1176,000 0,81373 0,42 
CD4 count 6977,000 1511,000 941,000 0,85382 0,39 
ARV treatment 7630,000 1281,000 1071,000 0,37139 0,71 
Previous TB diagnosis 9619,000 1112,000 881,000 2,40629 0,01 
TB treatment 7624,000 3107,000 1882,000 2,04934 0,04 
Granulomata 8662,500 2215,500 661,500 -3,66180 0,0001 
White cell count 9396,500 1334,500 1103,500 1,16550 0,25 
Haemoglobin 9055,500 1675,500 1180,500 -0,73611 0,46 
Platelet count 8843,000 1888,000 968,000 -1,92113 0,04 
Neutrophil count 7006,500 1249,500 1011,500 -0,16085 0,87 
Monocyte count 7152,500 975,500 785,500 1,62559 0,10 
Lymphocyte count 7260,500 995,500 805,500 1,54146 0,12 
Eosinophil count 6999,500 1001,500 830,500 0,98650 0,33 
 
 
* U value is the number of times observations in one sample precede observations in the other sample in the ranking. 
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Annexure B: National Health Laboratory Service (NHLS) Full Blood Count 




Parameter Adult male Adult female Units 
 Reference ranges Reference ranges    
 
 
White cell count 4,0-10,0 4,0-10,0 x 109/L 
Haemoglobin 13,0-17,0 12,0 -15,0 g/dL 
Platelet count 137-373 178-400 x 109/L 
Neutrophil count 2,0-7,5 2,0-7,5 x 109/L 
Monocyte count 0,18-0,8 0,18-0,8 x 109/L 
Lymphocyte count 1,0-4,0 1,0-4, 0 x 109/L 
Eosinophil count 0,00-0,45 0,00-0,45 x 109/L 








































Annexure C: Data collection sheet. 
 
Patient number: 
Date of bone marrow biopsy: Laboratory number: 





Prior TB diagnosis: 
Current TB treatment: 
Prior diagnosis of lymphoma/malignancy: 
 
Laboratory results 
CD4 count:   Date performed: 
White cell count:  
Haemoglobin:  
Platelet count:  
Neutrophil count:  
Monocyte count:  
Lymphocyte count:  
Eosinophil count:  
Mycobacterial blood cultures: 
Date performed: 
Result: 
Time to positivity: 
Mycobacterial bone marrow cultures: 
Result: 
Time to positivity: 






ZN & modified ZN results: 
 


















Annexure D: Fixation of Trephine Biopsies: NHLS Groote Schuur Hospital 
Standard Operating Procedure. 
        
  
STANDARD OPERATING PROCEDURE 
 
Title:   FIXATION OF TREPHINE BIOPSIES 
 
Document number: HAE0686      
 
Version number: 3 
 
 
Written by:  Dr Maureen Stein 
 
Checked by:  N/A 
 
Approved by:  F. Barton 
 





Fixation must preserve the tissue in such a manner that it will retain its original form and 
yet permit certain investigations. In the fixation of tissues the most important reactions 
are those, which stabilize the proteins. It seems that fixatives have the property of 
forming cross-links between proteins thereby forming a gel. Soluble proteins are fixed to 
structural proteins and thus rendered insoluble. Therefore, the whole structure is given 
some mechanical strength, which permits the subsequent processes to take place. 
Fixation normally takes place in aqueous solutions, although occasionally vapor is used. 
The type of investigation required will govern the choice of a fixative. In our laboratory, 











Mercuric chloride    50g 











Distilled water       1L 
 
Working Solution 
Stock solution    10ml 
Acetic acid                            0, 5 ml 
Formalin      1ml 
 
PROCEDURE 
1)   Place trephine in 10 ml Zenker's working solution. 
2)   Place on roller for 4 hours. 
3)   After 4 hours label cassettes and place trephine in appropriate ones. 
4)   Wash in running tap water for a minimum of 15 minutes to wash out all excess 
fixative thereby preventing the contamination of the decalcifying agent. 
 
Notes: Zenker's fluid is an excellent fixative for bone marrow biopsies. 
 
ADVANTAGES  
1)   Excellent for staining of nuclei and connective tissue. 
2)   Enhances staining. 
3)   Easy to prepare. 
 
DISADVANTAGES 
1)   After 24 hours the tissue becomes brittle and hardened. 
2)   The solution does not keep after the addition of acetic acid. 
3)   Prolonged fixation also causes shrinkage and damage to or loss of antigens on the 
cell surface, which will affect immune studies. 
4)   If the incorrect concentration or volume is used, it could alter the staining of the 
      tissue. 
FORMAL DECAL for trephines 
This must be made up once monthly – in the first week of the month in quantities of 4 
litres  
 
For 4 litres 
Formaldehyde     400ml 
Distilled water     3600ml 
 
Sodium di-hydrogen phosphate (NaH2PO4.2H20)  16g 
OR 
di-Sodium hydrogen phosphate (Na2HPO4.2H20)  26g 
 
Then discard 340ml of the above solution and add 
90% formic acid     175ml 
















Toxic by inhalation, in contact with the skin or if swallowed. 
Causes burns. 
Possible risks of irreversible effects. 
May cause sensitization on skin contact. 
Wear suitable protective clothing and gloves. 
Use only in well-ventilated areas. 
In case of contact with eyes, rinse immediately with plenty of water, report to safety 
officer and seek medical advice immediately. 




Causes severe burns. 
Do not breathe vapors. 
Wear suitable protective clothing and gloves. 
Use only in well-ventilated areas 
In case of contact with eyes, rinse immediately with plenty of water, report to safety 
officer and seek medical advice immediately. 
In case of accidental spill or if you feel unwell, report to safety officer and seek medical 
advice immediately 
 
THE TREPHINE PROCESSING PROCEDURE 
The first steps are perfomed in the C17 Haematology laboratory 
- The trephine in the cassette is placed in Formal Decal for 5 hours 
- It is then placed in water for 30 minutes. 
 
The trephine in the cassette is then referred to the Histology laboratory at Medical 
School for processing, wax embedding, cutting and H&E staining. The form “bone 
Marrow Delivery Receipt” is completed with the laboratory label, patient sticker and 




Handbook of Histopathological and Histochemical techniques, 3rd Edition. C.F.A. 



















Annexure E: Haematoxylin and Eosin stain: NHLS Groote Schuur Hospital 
Standard Operating Procedure. 
 
 
STANDARD OPERATING PROCEDURE 
 
Title:   HAEMATOXYLIN AND EOSIN STAIN   
   
Version number: 1 
 
 
Written by:  A. VISSER 
 
Checked by:  N/A 
 
 




To demonstrate the different tissue structures in sections which forms the basis of 




H&E staining usually means staining of nuclei by oxidized haematoxylin (haematein) 
through mordant bonds of metals such as aluminium, followed by counterstaining by 
eosin (a xanthene dye), which colours in varying shades the different tissue fibres and 
cytoplasms. A general tissue demonstration picture is produced. 
 
Haematoxylin itself is not a dye, the major oxidation product is haematein, a natural dye 
that is responsible for the colour properties. Haematein can be produced from 
haematoxylin in two ways, either by natural oxidation or by chemical oxidation. 
Natural oxidation (‘ripening’) by exposure to light and air can take between 3-4 months. 
Chemical oxidation uses sodium iodate. The iodate converts the haematoxylin to 
haematein almost instantaneously so the haematoxylin is available to use immediately. 
Haematein needs a mordant, ie a tissue-dye link and the most useful are aluminium and 
iron salts.  
 
Eosin is the most suitable dye to combine with an alum haematoxylin to demonstrate 











cytoplasm of different types of cells and between the different types of connective tissue 
fibres and matrices, by staining different shades of red and pink. In our laboratory we 









Mayer’s acid alum haematoxylin (add in the following order): 
1. Hot distilled water (± 70°C)      - 2000ml 
2. Haematoxylin (dissolve) – CI 75290    - 3g  
3. Potassium alum/Aluminium potassium sulphate (dissolve) - 100g 
4. Sodium iodate       - 0.4g 
5. Citric acid       - 2g 
6. Chloral hydrate (when cold)     - 100g  
 
Garvey’s modified Mayer’s haematoxylin: 
1. Dissolve 45g ammonium or potassium alum (aluminium ammonium- or 
aluminium potassium sulphate) in 900ml distilled water with the aid of heat. 
2. Dissolve 2.5g haematoxylin in 100ml absolute ethanol (alcohol). 
3. Combine above solutions and add 0.2g sodium iodate and 1g citric acid. 
Mix well. The solution is stable for several months. 
 
Eosin: 
• Solution 1: 1% Eosin Y (CI 45380) 
• Solution 2: 1% Phloxine B (CI 45410) 
• Solution 3: Mix 2 parts of 1% eosin and 1 part of 1% phloxine. The mixture must 
ripen for ± 2 weeks! 
• Solution 4: sol.3 is diluted with equal parts of  distilled water. The mixture must 
ripen for ± 2  weeks. This is the working solution – ‘Ready-for-use’. 
 
Scott’s tap water substitute: 
      Tap water       - 2000ml 











      Magnesium sulphate     - 40g 
      40% formaldehyde     - 20ml  
 
CARE: Chloral hydrate is toxic if swallowed; eosin is an irritant; formaldehyde is toxic. 
 
Method for routine H+E staining 
 
1. Bring sections to water. 
2. Haematoxylin – ½ to 2min. depending on freshness of solution. 
3. Rinse well in water. 
4. Blue in Scott’s – 30sec. 
5. Wash in running water – 2min. 
6. Counterstain in eosin – 2min. 




• Nuclei     - blue 
• Cytoplasm   - pink-red 




• H+E staining: eosin is easily removed in water and 96% alcohol. 
• Haematoxylin: chloral hydrate is an antioxidant/preservative and prevent 
bacterial growth; due to its toxicity, it is replaced with ethanol in Garvey’s 
haematoxylin. Ethanol is a more effective penetrator and bacteriostat. 
• Eosin: when fresh, the stain has a tendency to wash out easily. 
• Scott’s: 1% formalin is added to prevent the growth of mould. 
 
Safety considerations  
 
Refer to ‘Appendix: Safety Considerations for Special Stains’ at back of file or Material 
















v NHLS Histology Laboratory Special Stains Manual, Division of Anatomical 
Pathology, UCT Medical School, Groote Schuur Hospital, Cape Town. 
v Garvie, W; (1991) J. Histotechn 14(3): 164-165. 
v Manual of Histological Techniques and their Diagnostic Application; 
Bancroft J.D. and Cook, H.C.; Churchill Livingstone; 1994. 
v Cellular Pathology Technique – 4th Edition; Culling C.F.A., Allison R.T. and 
Barr W.T.; Butterworths; 1985. 



















































STANDARD OPERATING PROCEDURE 
 
Title:   ZIEHL-NEELSEN STAIN 
 
Version number: 1 
 
 
Written by:  A. Visser 
 
Checked by:  N/A 
 
 








Mycobacteria (eg. tubercle bacilli) have a lipid rich cell wall capable of taking up strong 
phenol-dye solutions so that they retain the dye upon subsequent differentiation in acid 
or alcohol (i.e. acid- and alcohol-fast). 
 
The phenol in the staining solution probably acts as a surface tension depressant to allow 






















 Supplied from Microbiology at C17. 
   OR: 
 Carbol Fuchsin: 
 Dissolve 1g Basic Fuchsin (CI 42510) in 10ml ethanol. 
 Dissolve 5g phenol (carbolic acid) in 100ml distilled water. 
 Mix the 2 solutions together. 
 Filter. 
(Basic Fuchsin: use the coarse granule, not the more purified type specified for 
Schiff’s reagent – CI 42510). 
Loeffler’s Methylene Blue: 
 Stock solution: 
  Absolute alcohol  - 100ml 
  Methylene Blue (CI 52015) - 0.8g 
 Working solution: 
  Distilled water   - 99ml 
  1% Potassium hydroxide - 1ml 
Stock solution   - 30ml 
Filter. 
 
CARE: Carbol Fuchsin solution includes reagents which are toxic; potassium hydroxide 




1. Take sections to water. 
2. Filter on Carbol Fuchsin. 
3. Flame slide until steam rises – leave for 5min. 
4. Flame slide again – leave for 5min. 
5. Rinse in water. 
6. Rinse in 1% acid alcohol until excess colour is removed. 
7. Rinse in water. 
8. Place slide in 25% sulphuric acid – 5-20min. 











10. Counterstain with Loeffler’s Methylene Blue – a few seconds. to 1min (‘sky’ 
blue). 
11. Rinse in water. 




• Acid fast bacilli, etc. - red 




• Avoid decalcification in strong acids as acid-fastness may be lost. 
• It is important to take through a control as the Carbol Fuchsin solutions 
deteriorate with age (and newly prepared solutions may not work). 
• Do not overstain with the counterstain. 




Refer to ‘Appendix: Safety Considerations for Special Stains’ at back of file or Material 





v NHLS Histology Laboratory Special Stains Manual, Division of Anatomical 
Pathology, UCT Medical School, Groote Schuur Hospital, Cape Town. 
v Manual of Histological Techniques and their Diagnostic Application; 




















Annexure G: Modified Ziehl-Neelsen stain: NHLS Groote Schuur Hospital 




STANDARD OPERATING PROCEDURE 
 
Title:   MODIFIED ZIEHL-NEELSEN STAIN 
 
Version number: 1 
 
 
Written by:  A. VISSER 
 
Checked by:  N/A 
 
 








Leprosy bacilli are much less acid- and alcohol-fast than tubercle bacilli and their lipid 
envelope is more easily affected by fat solvents, diminishing the staining reaction. 
Therefore, in this modification, differentiation with acid and alcohol is minimal and 
dewaxing is done in a mixture of a vegetable oil and xylene, or turpentine. 
 



















Please see ZN SOP. 
 





1. DO NOT TAKE TO WATER. Dewax in turpentine – 10min. 
2. Blot and rinse in water. 
3. Filter on Carbol-fuchsin solution (do not heat) – 20min. 
4. Rinse in water. 
5. Decolourise in 5% H2SO4 – 10-15min.  
6. Wash in running water – 5-10min. 
7. Counterstain lightly with Loeffler’s Methylene Blue. 




• Bacilli of M.Leprae and other mycobacteria, Nocardia asteroides - red 




Refer to ‘Appendix: Safety Considerations for Special Stains’ at back of file or Material 





v NHLS Histology Laboratory Special Stains Manual, Division of Anatomical 
Pathology, UCT Medical School, Groote Schuur Hospital, Cape Town. 
v Manual of Histological Techniques and their Diagnostic Application; 













Annexure H: Processing of MGIT (Mycobacterial Growth Indication Tubes), 
Lowenstein-Jensen slopes and MYCO/F Lytic bottles: NHLS Groote Schuur 
Hospital Standard Operating Procedure. 
    
  
STANDARD OPERATING PROCEDURE 
 
Title:   PROCESSING OF MGIT TUBES, LJ SLOPES and MYCO/F   
   LYTIC BOTTLES 
 
Document number: MIC0700  
 
Version number: 2 
 
 
Written by:  C. Visser 
 
Checked by:  N/A 
 
Approved by:  K. Mentoor 
 
 




This protocol describes the steps to be taken when placing MGIT tubes / LJ slopes into 
the incubator and when to remove the tubes / slopes. It also describes how to follow-up 
positive MGIT tubes / LJ slopes and Myco/F Lytic bottles. 
 
PRINCIPLE 
• The MGIT (mycobacterial growth identification) system is an automated, liquid 
medium based culture system for detecting mycobacterial growth. Once specimens 
have been inoculated, MGIT tubes are placed into a MGIT incubator unit. Growth is 
automatically evaluated by the machine by measuring changes in the fluorescence of 
the tube, which is influenced by a change in the oxygen tension in the medium. Once 
a change in fluorescence is measured, the tube is “flagged positive” by the incubator. 
• LJ (Lowenstein-Jensen) medium is a solid, egg based medium for culture of 
mycobacteria. It is often used as an adjunct to liquid based media, although there is 
some evidence that the MGIT media alone is sufficiently sensitive. Certain 
specimens (detailed in the specimen processing SOP) are inoculated onto LJ media 
as well. Growth is measured visually. 
• The Myco/F Lytic bottle is liquid culture used with the BACTEC 9000 blood culture 
system to allow the detection of mycobacteria. Growth is automatically evaluated by 











tube, which is influenced by a change in the oxygen tension in the medium. Once a 
change in fluorescence is measured, the bottle is “flagged positive” by the incubator. 
 
LIMITATIONS 
Refer to Isenberg, H.D; Clinical Microbiology Procedures Handbook, Volume 2, Bactec 
MGIT 960 Automated System section 7.4.2. 
 
SCOPE 
This SOP applies to all MGIT, LJ cultures and MycoF/ Lytic bottles which have been 
inoculated with either clinical or quality control samples. 
This SOP must be followed by any medical technologist / student medical technologist / 
technician / medical scientist / pathologist / pathology registrar who may be working in 
the laboratory and following up cultures. 
 
ABBREVIATIONS 
The following abbreviations are used in this SOP: 
MGIT    Mycobacterial Growth Indicator Tube 
LJ    Lowenstein-Jensen medium 
AUR    Auramine stain 
ZN    Ziehl-Neelsen stain 
LED    Light emitting diode 
2% BA   2% Blood agar 
LIS    Laboratory Information System 
 
EQUIPMENT AND SUPPLIES  
Biosafety cabinet 
Glass slides 
MGIT tubes (purchased from Becton Dickinson) 
LJ slopes (supplied by media laboratory) 
MycoF/ Lytic BACTEC culture bottles 
2% Blood agar plates (supplied by media laboratory) 
Bactec 960 MGIT incubator unit 
37 degree incubator (aerobic) 






M. tuberculosis is spread by the airborne route. Many laboratory procedures are 
accompanied by the formation of aerosols containing bacteria but most importantly, 
mycobacteria. All workers in the TB laboratory must be aware of aerosol formation and 
the dangers thereof. Any work that involves opening either a MGIT tube or an LJ 












Refer to the NHLS Safety Manual for additional information regarding Health and 
Safety. 
 
INCUBATION OF MGIT TUBES 
i. Open the drawer of the MGIT incubator unit. 
ii. Select the ‘insert tube’ icon. 
iii. The MGIT tube has two barcodes on it – one printed on the tube by the 
manufacturer and the other the barcode on the laboratory generated label (this 
barcode is associated with the laboratory number). First scan the MGIT tube’s 
barcode into the MGIT incubator, and then scan the laboratory generated 
barcode. The barcode scanner is located on the front of the incubator 
iv. Insert the MGIT tube into the spot indicated in the MGIT drawer by the 
red/green LED. 
v. If a specimen is in a container other than a MGIT tube (such as a large bone 
specimen) incubate it in the freestanding aerobic (37oC) incubator. This culture 
will be inspected manually (see later) 
 
PROCESSING OF POSITIVE MGIT TUBES  
i. Every morning remove all MGIT tubes that have flagged positive. This is 
performed daily from Monday to Friday, apart from public holidays. 
ii. Open the drawer of the MGIT incubator unit and press the positive icon on the 
screen (picture of a tube with a “+”in it) and remove the MGIT tubes indicated 
by the LED. Keep MGIT's from each machine separate. 
iii. Print an “unloaded positives” report for each unit. Press the printer icon (picture 
of a printer), and then the positive vial icon. See appendix A for example of an 
unloaded positives report. 
iv. All tubes that have already been processed in the preceding week should be 
returned to their corresponding MGIT units.  Only tubes that have not flagged 
positive before and those that last flagged positive more than a week ago are to 




















and was followed 
up ≤7 days ago 




Place tube back in 
the MGIT unit  
Prepare ZN slide. Inoculate 
MGIT onto 2% BA 
ZN pos – record 









see Table 1) 
Place back in the 
MGIT unit 
Read 2% BA plate 
and record on the 
unloaded positive 
report.  
Pos after > 1 day 
Replace tube in 
MGIT incubator 
and repeat ZN 
and 2% BA after 
7 days. 
No growth 





growth on 2% BA, 
will need 
decontamination 
Pos again the 
next day 
Send out as 
contaminated if 
original specimen had 
been decontaminated.  
If original specimen 
was not initially 
decontaminated or, if 














A: TUBES PREVIOUSLY REMOVED < 7 DAYS AGO 
i. Return all these MGIT tubes to the appropriate MGIT unit within 5 hours of 
removal. Barcode the MGIT tube back into the MGIT unit (only the MGIT 
tube’s barcode needs to be scanned). 
 
B: NEW POSITIVES AND TUBES PREVIOUSLY REMOVED > 7 DAYS AGO 
i. For each MGIT, label a slide for ZN staining and a quadrant on 2% BA plate to 
check for contamination. 
ii. Work under the hood when working with the MGIT tubes. 
iii. Place a drop of precipitating fluid on the slide to ensure adherence of the smear. 
iv. Aspirate (fish) approximately 0,1ml from the bottom of the MGIT tube, inoculate 
the BA quadrant and prepare a slide for a ZN. 
v. Dry the slides under the hood and stain according to the ZN stain technique. 
vi. Incubate the 2% BA plates overnight in the CO2 incubator. 
vii. Once the ZN has been read, record results on the unloaded positive report. Slides 
can be discarded.  
viii. If the ZN is negative, date the MGIT tube and return to the appropriate MGIT 
unit within 5 hours of removal. Only the MGIT tube’s barcode needs to be 
scanned. 
ix. If the ZN is positive, refer to the ‘Positve MGIT's / LJ’s for Identification’ flow 
diagram UNLESS: 
o the ZN appearance is typical of M. tuberculosis (with cording and 
beaded appearance) and  
o the initial auramine performed on the specimen was positive and 
o sensitivity testing has not been requested and the specimen was a 
sputum, a tracheal aspirate or induced sputum 
In the above situation the specimen can be sent out with the comment “MTBID” 
resulted on the LIS. If in doubt, consult a senior technologist or a pathologist. 
x. Place MGIT tubes or LJ’s in the ‘awaiting TBPCR’ box or the ‘awaiting HAIN’ 
box. 
xi. If ZN appears atypical, inoculate on LJ slope for a possible MOTT ID.  
xii. Read the 2% BA plates and record the results on the unloaded positive report. 
xiii. Growth on 2% BA from MGIT's that are ZN positive must be entered on the LIS. 
xiv. Refer to the Flow Chart or Table 1 for the appropriate course of action depending 
on the results of the 2% BA culture and the ZN. 
xv. If the culture is contaminated with an organism that may be a Nocardia, consult 
with a pathologist or registrar to determine whether the organism should be 
identified and reported. 
xvi. ALWAYS remember to check whether an LJ slope was inoculated as well. If a 
specimen is being discarded and an LJ was inoculated, the LJ can be incubated 






















Specimen type ZN performed 
on MGIT 
Action 
Nag Growth Any specimen 
that has been 
decontaminated 
Negative Send out as contaminated 
Nag Growth Any specimen 
that was NOT 
decontaminated 
Negative Decontaminate  





Any Negative Re-incubate in MGIT 
machine for a further 7 days 
and re-assess with ZN and 
2% BA at that stage 
Nag No 
growth 
Any Pos Check flow diagram (page 8) 





Sputum Pos  Not for PCR unless 
sensitivity testing required, 
or unless ZN on MGIT 
doesn’t resemble M. 
tuberculosis.  





Any, other than 
sputum 
Pos Into PCR box 
 
 
PROCESSING OF NEGATIVE MGIT TUBES 
This is performed on Monday to Friday, except for public holidays.  
With the MGIT 960 instrument tubes are held for 42 days before they are removed as 
negative. Those tubes ready for removal from the system will be indicated on the display 
and on the appropriate drawer. 
 
i. Open the drawer of the instrument, press the negative icon (bottle with a “-“on 
it), and remove the tubes indicated by the LED's. 
ii. Print an “unloaded negatives” report by pressing the printer icon, and then the 
icon of a bottle with a “-“on it. See appendix B for an example of an unloaded 
negatives report. 
iii. Correlate the MGIT accession number to the accession number on the unloaded 
negative report and tick each one and sign the report, 
iv. Visually inspect all negative MGIT tubes.  If there appears to be granules, 
perform a ZN.  If the ZN is positive, subculture to a LJ slope to confirm viability 











v. If ZN is negative send out as negative. 
vi. Using the MGIT, enter results on the LIS. 
vii. If any specimens have had LJ slopes inoculated, remove the corresponding LJ 
slopes from the incubator and enter the result of the LIS. 
viii. The negative MGIT tubes and LJ's are sent for autoclaving before being 
discarded. 
 
PROCESSING OF MGIT CULTURES NOT IN THE MGIT INCUBATOR 
These are specimens such as bone that were too large to fit into a normal MGIT tube. 
 
i. Examine the culture medium weekly (usually a Monday) for any sign of visible 
turbidity 
ii. If the bottle is turbid, proceed as for a positive MGIT culture (sections A or B 
depending on the age of the culture) 
iii. If there is no visible growth after 6 weeks, perform a ZN stain on the liquid in the 
bottle. 
• If the ZN is negative, send out as No Growth 
• If the ZN is positive, put aside for PCR. 
 
INCUBATION OF LJ SLOPES 
Slant the LJ slopes overnight with the caps loose in the slanting rack in the CO2 
incubator. The following morning tighten the caps and store on a labeled (“1st week”, 
“2nd week” etc) tray in the 37ºC incubator. A “TB week” stretches from Monday to 
Friday. 
 
READING OF LJ SLOPES 
A: ROUTINE READING OF SLOPES 
 
Usually on Mondays (if there is a long weekend –the first working day of the week) 
i. Rotate week indicators on the LJ trays 
ii. Examine the LJ slopes for visible growth.  
iii. Any slopes with growth should be put aside. 
iv. Slopes at the end of week 6 must be discarded if no growth. Record the result on 
the LIS. 
v. Aerate LJ slopes in week 3 and the “awaiting ID” racks as follows: 
• Loosen caps – DO NOT REMOVE – and replace bottle in rack. 
• Allow to stand on the bench until bottles have cooled to room temperature. 
• Re-incubate overnight with the caps loose. 
• Remove rack the following day. Allow to cool again and then tighten caps before 

















B: LJ SLOPES WITH VISIBLE GROWTH: 
i. Find out if the corresponding MGIT has flagged positive yet. If so, work from 
the MGIT tube, and use the LJ as a backup if necessary. Enter the result of the LJ 
on the LIS. 
ii. If the MGIT has not flagged yet, proceed by preparing a ZN slide.  
iii. Using a cotton swab, remove a portion of the growth from the LJ slope, prepare a 
slide for ZN. 
iv. If the ZN is positive, place the LJ in the “PCR” box 
v. If the ZN is negative, and the slope appears contaminated, enter the result on the 
LIS as contaminated and discard the LJ slope.  
vi. If the culture is contaminated with an organism that may be a Nocardia, consult 
with a pathologist or registrar to determine whether the organism should be 
identified and reported. 
 
MYCO/F LYTIC BOTTLES 
When bottle flags positive it will be sent from the blood culture lab to the TB laboratory 
with its corresponding form. 
i Prepare a slide for a Gram and ZN stain. 
ii Sub an aliquot from the bottle onto a 2% BA and incubate under C02 conditions. 
iii Read the ZN and Gram stain.  If the ZN and Gram stain reveal no organisms 
return the Myco/F Lytic bottle to the blood culture machine within 3 hours. 
iv If the bottle repeatedly flags positive in the blood culture machine (this usually 
happens with bone marrow specimens), subculture the bottle onto a LJ slope. 
Place this LJ slope together with its corresponding Myco/F Lytic bottle in the 
sloping tray and the following day place into the ‘Awaiting further identification’ 
box and incubate off-line for 6 weeks.  Read the LJ weekly as indicated above. 
v If the ZN is positive, subculture the Myco/F Lytic bottle onto an LJ slope. Enter 
a provisional culture result onto the LIS as follows: 
o  Result: RES (result to follow) 
o Gram:  NBO or gram result 
o Organism: MYCOB (if TBZ positive) 
vi Order a TBZ and result as “pos” or “neg”. 
vii If the ZN is negative and the Gram stain shows the presence of organisms return 
the Myco/F Lytic bottle with the corresponding form to the blood culture 
laboratory for follow up. Before returning the bottle to the Blood Culture Lab, 
remove about 10ml fluid from the Myco/F Lytic bottle into a Sterilin® tube. 




Although microscopy is the primary means of diagnosing TB in South Africa, culture is 
sometimes indicated to make a diagnosis of TB. Detection of mycobacterial growth from 
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MTB PCR IDENTIFICATION 
PURPOSE 
The purpose of this SOP is to describe how acid fast organisms that are growing in 
either a MGIT or LJ culture are identified as M. tuberculosis complex by means of a 
specific PCR (polymerase chain reaction) assay. 
 
PRINCIPLE 
A PCR assay was developed for the amplification of a 336 – bp repetitive fragment in 
the chromosome of Mycobacterium tuberculosis. Briefly, organisms are boiled to kill 
them and release their DNA, the DNA is used as a template in a PCR assay where the 
specific fragment of mycobacterial DNA, if present, is amplified by means of a 
thermostable polymerase enzyme. The presence of the specific amplification product is 
detected by electrophoresing the sample on an agarose gel, and visualising the DNA 
under ultraviolet light. The assay is specific for Mycobacterium tuberculosis complex 
and can be used to detect the amount of DNA present in less than 10 organisms.  
 
LIMITATIONS 
• Use of incorrect primers or expired primers. 
• Incorrect reagents and inaccurate volumes used in the mastermix. 
• Incorrect connection of electrodes on the gel tank. 











• Cross contamination while loading gels. 
• A negative test result does not exclude the possibility of infection. 
 
SCOPE 
This SOP applies to all MGIT tubes or LJ slopes which have cultured acid fast bacilli.  
 
RESPONSIBILITY 
This SOP must be followed by any medical technologist / student medical technologist / 
medical scientists / pathologist / pathology registrar who may be working in the 
laboratory and processing specimens for mycobacterial culture. 
 
ABBREVIATIONS 
The following abbreviations are used in this SOP: 
TB    Tuberculosis 
MOTT    Mycobacterium other than tuberculosis   
MGIT    Mycobacterial Growth Indicator Tube 
LJ    Lowensten-Jensen medium 
AUR    Auramine stain 
ZN    Ziehl-Neelsen stain 
PCR    Polymerase Chain Reaction 
DNA    Deoxyribonucleic acid 
DMSO    Di-Methyl Sulfoxide 
dNTPs    Deoxy-nucleotide triphosphate mixture 
MgCl2    Magnesium chloride 
TE    Tris-EDTA 
TAE    Tris-acetate-EDTA 
LIS    Laboratory Information System 
2% BA   2 % Blood Agar 
 
 
EQUIPMENT AND SUPPLIES  
§ Biosafety cabinet 
§ 1,5ml Eppendorf tubes 
§ 0,5ml Eppendorf tubes 
§ Air displacement pipettes: 1000ul, 200ul, 20ul. 
§ Filtered pipette tips (aerosol resistant tips) 
§ PCR thermocycler 
§ Polypropylene tubes 15ml capacity (NOT polystyrene tubes) 
§ Heating Block 
§ Microwave oven 
§ Electrophoresis tanks 
§ Electrophoresis trays 
§ Gel combs (18-20 teeth ideally)  
§ Power-pack for electrophoresis 
§ UV transilluminator 











§ Rubber gloves 
§ Bench top centrifuge 
 
REAGENTS 
Taq polymerase    purchased commercially 
MgCl2 (25mM)    purchased commercially 
PCR buffer     purchased commercially 
dNTPs        purchased commercially 
Ultra pure water    purchased commercially 
Agarose     purchased commercially 
DMSO      purchased commercially 
TE buffer (10mM Tris, 1mM EDTA pH 7.6)  supplied by media lab 
Loading buffer (bromophenol blue and sucrose) supplied by media lab 
Ethidium bromide (5mg / ml stock solution) made up in-house 
 
TAE buffer supplied by media lab as 50xTAE 
Make 1X TAE with either of the following volumes: 
  50X TAE   Distilled water  
  20ml    980ml 
  40ml    1960ml 
 
Primers K1 and S2 synthesised by UCT dept cell biology 
The primers are diluted to a working stock of 20pmol/ul 
  K1: 5’ - GCC AGA ACC GAC CAA CCC GCC GAT A – 3’ 
  S2: 5’ - GCG GCT CGG GCG GCG TCG GTG GCT T -3’ 
 
SAFETY PRECAUTIONS 
M. tuberculosis is spread by the airborne route. Many laboratory procedures are 
accompanied by the formation of aerosols containing bacteria but most importantly, 
mycobacteria. The technologist must be aware of aerosol formation and the dangers 
thereof. Therefore all procedures using live cultures, as far as possible, should be 
performed in the laminar flow cabinet. Once the samples have been boiled, the 
organisms are dead and do not pose an infection risk. 
 
Ethidium bromide is potentially carcinogenic and teratogenic.  Nitrile gloves must be 
worn whenever working with the solution. Hands must be washed after any use of 
ethidium bromide – even if gloves were worn as well. For more details on the handling 
and disposal of ethidium bromide and ethidium bromide containing gels, refer to the 
appropriate SOP (Molecular: Handling of Ethidium Bromide). 
 
SPECIMENS FROM OTHER LABORATORIES 
In addition to the MGIT or LJ cultures from the TB laboratory at Groote Schuur 
Hospital, cultures from both Tygerberg Hospital and 2 Military Hospital are sent for 
PCR identification of mycobacteria 
Specimens from Tygerberg Hospital usually arrive once a week.  











ii. Sort MGIT's according to the referral sheet provided by TBH.  
iii. If all the specimens that are listed on the referral sheet have arrived, sign the 
sheet, photocopy it, and send the copy back to the Tygerberg Hospital TB 
laboratory. If any specimens are missing, contact the Tygerberg TB laboratory to 
inform them. 
iv. Register each of the specimens with a GSH laboratory number, and label the 
forms and MGIT tubes with a Groote Schuur lab number (SCH prefix).  
v. Place a red sticker on the MGIT tubes / LJ slopes for HAIN PCR and separate 
the MGIT tubes and LJ slopes into awaiting HAIN and TBPCR boxes.  
 
SORTING OF POSITIVE CULTURES 
All positive cultures where TBCUL has been requested and certain trials will be 
included in TBPCR’s. 
If a patient has more than one positive culture, only one of those need to be identified by 
PCR, unless samples are taken >1 month apart. If a specimen is positive in both the 
MGIT and on the LJ slope, it is only necessary to confirm one of these cultures as 
Mycobacterium tuberculosis. If the growth on the LJ slope is heavy use this for PCR 
instead of the MGIT culture. 
i. Print a TBPCR worksheet from the LIS: 
Select worksheet 
Area: MTB F5 
 Grp: * F7 
Code: MTB Close – choose Y  
ii. Arrange the MGIT tubes / LJ slopes / BacT– ALERT bottles according to the 
PCR worksheet. 




The following controls are included in every PCR run: 
i. A negative control (TE buffer as described below) every 10th specimen  
ii. Negative control – water (set up at time of preparing mastermix) 
iii. Mycobacterium tuberculosis (H37Rv) 
All the controls must be included on the PCR worksheet 
 
PCR ASSAY 
The PCR assay is carried out in 4 different areas of the laboratory in order to minimise 
the chance of cross contamination. It is vital that the different steps of the PCR 
procedure are carried out in the appropriate area of the laboratory. 
a) Preparation of culture suspensions for PCR (area 1) 
b) Preparation of PCR amplification mixtures (area 2) 
c) Addition of template (area 3) 














Extraction of DNA – (TB laboratory): 
For MGIT tubes and BacT-Alert bottles:  
Aliquot approximately 1 – 1.5ml of the culture fluid into the correctly labelled tube.  
 
For LJ slopes: 
Aliquot 1 – 1.5ml of TE buffer into an Eppendorf tube. 
Using a sterile cotton swab, make a heavy suspension of the organism from the LJ slope 
in the TE buffer. 
 
For TE control: 
Aliquot 1 -1.5ml TE buffer into an Eppendorf tube 
  
i. Check that the number on the tube and on the specimen correspond. 
ii. Tighten the caps of the tubes securely to prevent the release of the contents 
during the heating step. 
iii. Switch on the heating block and allow too reach temperature of 95°C.  
iv. Place the tubes in the heating block and incubate for 30 minutes.   
v. After boiling, place the tubes at 4ºC for at least 20 minutes to allow cooling and 
condensation to take place.   
vi. Centrifuge for 3 - 5 minutes at 3200 rpm in a bench top centrifuge.  
vii. Return tubes to racks.  The cooling and centrifugation steps ensure that all 
products of the boiling procedure, including released DNA, are confined to the 
bottom of the tube.  Thus, the possibility of contamination of the environment 
with target DNA when the tubes are opened, is reduced.   
viii. The boiled DNA suspensions are stored at 4ºC if not used immediately. 
 
Preparation of reagents – area 2: 
PCR reagent mixtures are made up in the PCR ‘clean’ room. PCR cleanliness is very 
important.  Hands must be washed and laboratory coats removed before entering this 
area.  Pens, paper and all PCR ‘clean’ reagents are available so it is not necessary to 
bring anything additional into this room. Nothing leaves this area except you and the 
newly aliquoted PCR master mixes. For more detail on the use of the PCR clean room, 
refer to the SOP Molecular: General techniques. 
 
Make up a master-mix using the following formula. All the reagents except water and 
DMSO are stored at -20°C (±2°) in the clean room. DMSO and water are kept at room 
temperature in the clean room.  
§ Multiply the volume of each component by the number of tests being done plus 1 
(e.g. 31 tests plus 1 = 32). Don’t forget to include the appropriate number of 
controls. This allows for the inevitable loss of minute volumes while pipetting.  
 
 
Formula for TB PCR assay 
Ultra pure water 19,7µl 











MgCl2  (25mM) 3µl 
DMSO 5µl 
dNTP’s 2µl 
Primer S2 (20pmol/ul) 2,5ul 
Primer K1 (20pmol/ul) 2,5µl 




i. Add all the components to a polypropylene tube. 
ii. Mix well by pipetting up and down repeatedly 5-10 times. 
iii. Add Taq polymerase enzyme: 0.3 µl per reaction (the concentration is 5 units / 
1µl). Mix well once more. It is very important the two mixing steps be 
performed. 
iv. Aliquot 40ul of the mastermix into 0,5ml eppendorf PCR tubes 
v. To one tube of mastermix add 10ul of sterile water from the PCR clean room. 
This serves as the negative control with water. 
vi. Discard any remaining mastermix  
vii. Place mastermix tubes into ice blocks and store at -20°C. 
 
 
Addition of DNA (area 3): 
i. Place the mastermix tubes inside the laminar flow hood, and the tubes with 
extracted DNA template outside the hood. There should only be one tube with 
template DNA in the hood at any one time. Ensure that all mastermix tubes are 
closed before bringing a new tube of DNA template into the hood. 
ii. Aspirate 10ul of the DNA mixture from the tube by tilting the tube and allowing 
only the pipette tip to enter the tube opening 
iii. Load the appropriate PCR tube with 10µl of DNA preparation, using filter tipped 
aerosol resistant tips.  The 10µl volume is added to and mixed with the PCR 
mixture by ticturating 2-3 times.  One tube should have no DNA added – the 
tube with mastermix and water that was added in the PCR clean room (negative 
control). 
 
Amplification – area 4: 
The amplification steps are performed in the DNA amplification laboratory. 
Thermocycler 6 has been programmed with the appropriate conditions. 
§ Initial denaturation step: 1 cycle for 8 minutes @ 95°C 
§ 40 cycles of 95°C (denaturation) for 25 seconds alternating with 69°C (annealing 
and extension) for 60 seconds.  
§ Indefinite hold at 4ºC. 
i. Turn on the thermocycler 
ii. Transfer the tubes into the thermocycler and close the lid 
iii. Press “Run” (the F1 key) – a list of programmes appears on the display 
iv. Use the down arrow to highlight the “tb-pcr” programme 











vi. Once the run has finished (the samples are in the indefinite 4ºC hold cycle), turn 
off the thermocycler (or quit the programme) and remove the tubes. 
Alternatively, the cycle can be set up manually on one of the other thermocyclers. Refer 
to the manufacturer’s instructions for details of how to do this, or ask a senior member 
of staff. If you are unsure, please ask rather than fiddle! 
 
DETECTION OF PCR PRODUCT  
Amplification of the specific PCR product is determined by agarose gel electrophoresis. 
For details on the running of agarose gels, refer to the Molecular: General techniques 
SOP 
The following is a brief description of the agarose gel electrophoresis methodology. 
i. Prepare a 3% agarose gel by adding 3g agarose to 100 ml TAE buffer, and 
heating in the microwave until completely dissolved 
ii. Allow the agarose to cool to about 50-60ºC (the bottle can be held comfortably in 
your hand without burning)  
iii. While waiting for the agarose to cool, prepare a gel tray by taping the open ends 
closed with masking tape. 
iv. Add ethidium bromide to the gel – 2ul of stock (5mg/ml) to 100 ml agarose. The 
final ethidium bromide concentration is 0,1ug/ml. Remember to wear gloves 
when working with ethidium bromide, and to discard pipette tips into the sharps 
container. 
v. Pour the cooled agarose into the tray to a depth of about 7mm 
vi. If there are slots in the gel tray for the combs, these should be used. If there are 
no slots, place a comb about 5mm from the end of the tray, and another comb 
about halfway down the gel. The second comb should be placed such that it is 
approximately 4 cm from the first comb, and there is at least 4 cm between the 
second comb and the end of the gel. Allow the gel to cool and set completely 
before gently removing the combs. 
vii. Place the gels into running tanks containing just enough 1XTAE running buffer 
to cover them.  
viii. If there is any excess gel in the bottle, store it in the dark (ethidium bromide is 
light sensitive). The gel can be reused by melting it in the microwave.   
ix. Add 10ul loading buffer to the amplification mixtures and mix well.  .   
x. Using a pipette, aspirate 10ul of the amplification product and dye, place the tip 
of the pipette at the corner of an empty well in the gel, and slowly inject the 
mixture into the well. The dye allows one to visualise the mixture settling in the 
bottom of the well. 
xi. Load the samples sequentially into the wells. 
xii. Molecular weight marker VIII (10ul) is loaded into the first and last well of 
every line of wells. 
xiii. To prevent cross contamination it is advisable to leave a blank space between the 
negative control and the patient sample. 
xiv. Once all the samples have been loaded, place the lid on the tank, and DNA will 
migrate from the negative (black) electrode to the positive (red) electrode.. 
xv. Turn on the powerpack and electrophorese the gel at 100V.  During loading (and 











stable (no knocking or bumping) so that PCR mixture load from one well is not 
carried over to other wells.  
xvi. The dye allows one to visualise how far the samples have migrated. The power 
can be turned off when either: 
o The dye has migrated about 4,5cm (ie virtually touching the next set of 
wells if two rows of wells were used)  
OR 
o If one set of wells were used, the dye should have migrated at least 4,5cm 
and at most to within 0,5cm of the end of the gel. 
xvii. Remove gels carefully and view on the UV transilluminator.   
xviii. Photograph using the digital camera (see PCR-Digital Camera).  
xix. Name the file with the current month, date and year and save in the TB PCR 
folder. Print a copy of the picture.  
 
RESULTS 
The controls must be checked first. The expected results are: 
H37 RV   336 bp band 
TE control   no amplification 
Mastermix / water control no amplification 
If the controls have not worked as expected, discuss it with the technologist in charge of 
the TB lab or one of the pathologists. The following is a general description of the 
approach to failed controls. 
 
Positive H37RV has not amplified: 
§ If the H37RV controls has not amplified, the batch must be repeated (the 
positives are also repeated in case the positive control was mistakenly loaded 
into the wrong lane).  
§ The problem must always be discussed with the technologist in charge of the TB 
lab, or one of the pathologists to discuss further troubleshooting options 
 
The negative control (TE or water) is positive: 
§ Repeat entire batch 
 
READING PCR RESULTS 
i. M. tuberculosis PCR product is indicated by the presence of a 336bp fragment. 
The result is reported as Mycobacterium tuberculosis complex.  
ii. M. bovis and M. bovis BCG gives a 260bp fragment.   
iii. Other mycobacterial species give a negative PCR result (no amplification).   
iv. Label the lanes on the photograph to correspond with the number in the PCR 
worksheet. 
v. Transcribe the results onto the PCR worksheet and the LIS.  
vi. If PCR is negative and there is no record of growth on 2% BA: 
§ subculture onto an LJ slope and incubate at 37°C and move to the 
‘Awaiting Identification’ box the following day 
§ complete an ‘Awaiting Identification’ form  











§ Incubate the MGIT tube in the ‘Awaiting Identification’ box 
§ Complete an ‘Awaiting Identification’ form.  
Discuss with the technologist in charge of the TB lab, or with one of the 
pathologists regarding    further identification procedures. Record all decisions in 
this regard on the request form. 
vii. If more than one specimen comes up positive in the MGIT culture, from the 
same patient, it is only necessary to confirm ID by PCR on one specimen. Send 
out each report as M. tuberculosis complex. 
viii. All isolates that appear to be M. bovis BCG (i.e. 260 bp fragment) should be 
confirmed by the specific multiplex PCR for M. bovis BCG. Repeat the 
electrophoresis of any specimen where a positive result is based on the presence 
of a weak 336bp band adjacent to a bright 336bp band.  Always be aware that a 
positive result in such cases might be due to the carry-over of positive product 
from one well into an adjacent well.   
 
CLINICAL APPLICATION 
It is important to positively identify mycobacteria as M. tuberculosis for the following 
reasons: 
§ Treatment of tuberculosis differs significantly from treatment of other 
mycobacterial infections 
§ Non-tuberculous mycobacteria may be non-pathogenic in some instances, wheres 
M. tuberculosis is always regarded as a pathogen. 
§ Infection with M. tuberculosis has public health implications 
Use of PCR provides a quick and reliable way of positively identifying cultures of acid 
fast bacilli as M. tuberculosis, shortening the time to a final report being issued and thus 
hopefully allowing for more rapid initiation of therapy and contact tracing. 
 
NOTE: 
Positive TB culture results from patients at Red Cross Children’s Hospital are notified 
via email to Infectious Disease clinicians at Red Cross Children’s Hospital. 
 
.ATTACHMENTS: 
– Master Mix Record Sheet 
– TB Primer Reconstitution Record Sheet 
– In-house PCR Worklist 
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